ClinicalTrials.gg
CompletedNCT02544217Updated Oct 18, 2021Results posted

A Dose-escalating Clinical Trial With KH176

A Phase 1 interventional study of KH176 and placebo in MELAS, LHON and Leigh Syndrome, sponsored by Khondrion BV. Completed at 1 site in Belgium. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-10-18.

Sponsored by Khondrion BV · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

Mitochondrial Diseases are rare progressive, multi-system, often early fatal disorders affecting both children and adults. KH176 is a novel chemical entity currently under development for the treatment of inherited mitochondrial diseases, including MELAS (Mitochondrial Encephalomyopathy, Lactic acidosis, and Stroke-like episodes), Leigh's Disease and Leber's Hereditary Optic Neuropathy (LHON). KH176 is a potent intracellular redox modulating agent targeting the reactive oxygen species which are important in the pathogenesis of disorders of mitochondrial oxidative phosphorylation. After demonstrating a favourable safety profile in the pre-clinical testing, the safety, tolerability and pharmacokinetic and pharmacodynamic characteristics of the compound will now be evaluated in healthy male subjects in this trial

02

Conditions studied

  • MELAS
  • LHON
  • Leigh Syndrome
  • Mitochondrial Disease
  • Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation
03

In context

MELAS Syndrome

37 studies on the registry are indexed under MELAS Syndrome; 8 are open to participants now.

This study's enrollment of 32 is above the median of 24 across 29 interventional studies indexed under MELAS Syndrome.

Browse MELAS Syndrome studies →

Lead sponsor

Khondrion BV is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy as assessed by medical history, physical examination, Vital Signs, Clinical Laboratory,

Exclusion criteria

Exclusion Criteria:

  • Allergies,
  • Concomitant medication,
  • concomitant disease,
  • relevant surgery,
  • recent blood donation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Single Escalating

    2 alternating groups receiving escalating single doses of active/placebo

    Drug: KH176 · Drug: placebo

  • Experimental
    Multiple Escalating

    3 multiple escalating groups, receiving active/placebo

    Drug: KH176 · Drug: placebo

Interventions

06

What researchers measure

Primary outcomes

  1. SAD: Change From Baseline in ECG Results by Timepoint: Corrected QT Interval According to Fridericia's Formula (QTcF)

    The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation of the corrected QT intervals the average of the 3 recordings will be taken as baseline. Other ECG recordings will be singlet (one recording of at least 3 complexes) prior to dosing. QTcF is calculated as the quotient between the QT interval in milliseconds and the cube root of the RR interval in seconds, according to Fridericia's formula.

    Time frame: Baseline, 1, 2, 4, 6, 8, 12, 24 hours, 7 day follow up

  2. Pharmacodynamics of KH176

    Change from baseline in biochemistry related to Oxidative Phosphorylation (OXPHOS) (glutathione, lactate); MAD group

    Time frame: Day 1, day 7

  3. Relationship to Study Drug and Severity of Treatment-emergent Adverse Events

    Time frame: 4 months

  4. Change From Baseline in Hematology Laboratory Test Results by Timepoint: Red Blood Cell Count. SAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days after last dosing)

  5. Change From Baseline in Hematology Laboratory Test Results by Timepoint: Erythrocyte Sedimentation Rate (SAD Group)

    Time frame: Baseline (pre-dose Day1), 24h post dose, FU (7 days after last dosing)

  6. Change From Baseline in Hematology Laboratory Test Results by Timepoint: Erythrocyte Sedimentation Rate MAD Group

    Time frame: Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days after last dosing)

  7. Change From Baseline in Hematology Laboratory Test Results by Timepoint: Hematocrit SAD Group

    Hematocrit is a measure of the ratio of red blood cells (RBCs) in the blood by volume. Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline (pre-dose Day 1), 24 h postdose, FU (7 days after last dosing)

  8. Change From Baseline in Hematology Laboratory Test Results by Timepoint: Mean Corpuscular Haemoglobin. SAD

    Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline (pre-dose Day 1), 24 h post dose, FU (7 days after last dosing)

  9. Change From Baseline in Hematology Laboratory Test Results by Timepoint: Mean Corpuscular Hemoglobin Concentration - SAD

    Erythrocyte mean corpuscular hemoglobin concentration (MCHC) is a measure of the average concentration of hemoglobin per red blood cell. Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline (pre-dose Day 1), 24 h post dose, FU (7 days after last dosing)

  10. Change From Baseline in Hematology Laboratory Test Results by Timepoint: Mean Corpuscular Volume - SAD

    Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline (pre-dose Day 1), 24 h post dose, FU (7 days after last dosing)

  11. MAD: Change From Baseline in ECG Results by Time Point: QTcF

    The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation of the corrected QT intervals the average of the 3 recordings will be taken as baseline. Other ECG recordings will be singlet (one recording of at least 3 complexes) prior to dosing, or around the expected Cmax on Day 1 or 7 for the multiple-dose part. QTcF is calculated as the quotient between the QT interval in milliseconds and the cube root of the RR interval in seconds, according to Fridericia's formula.

    Time frame: Baseline, Day1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7

  12. Change From Baseline in Hematology Laboratory Test Results by Timepoint: White Blood Cell Count. SAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days after last dosing)

  13. Change From Baseline in Hematology Laboratory Test Results by Timepoint: Lymphocytes. SAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)

  14. Change From Baseline in Hematology Laboratory Test Results by Timepoint: Neutrophils. SAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days after last dosing)

  15. Change From Baseline in Hematology Laboratory Test Results by Timepoint: Hematocrit MAD Group

    Hematocrit is a measure of the ratio of red blood cells (RBCs) in the blood by volume. Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value

    Time frame: Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)

  16. Change From Baseline in Hematology Laboratory Test Results by Timepoint: Eosinophils. SAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days after last dosing)

  17. Change From Baseline in Hematology Laboratory Test Results by Timepoint: Thrombocytes. SAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline (pre-dose Day 1), 24h, FU (7 days post-dose)

  18. Change From Baseline in Hematology Laboratory Test Results by Timepoint: Basophils. SAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value ateach timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post-dose)

  19. Change From Baseline in Hematology Laboratory Test Results by Timepoint: Monocytes. SAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post-dose)

  20. Change From Baseline in Hematology Laboratory Test Results by Timepoint: Mean Corpuscular Volume. MAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)

  21. Change From Baseline in Hematology Laboratory Test Results by Timepoint: Hemoglobin. MAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)

  22. Change From Baseline in Hematology Laboratory Test Results by Timepoint: White Blood Cell Count. MAD

    Blood samples were collected from participants at the indicated time points for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each time point are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)

  23. Change From Baseline in Hematology Laboratory Test Results by Timepoint: Neutrophils. MAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)

  24. Change From Baseline in Hematology Laboratory Test Results by Timepoint: Mean Corpuscular Haemoglobin Concentration. MAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)

  25. Change From Baseline in Hematology Laboratory Test Results by Timepoint: Lymphocytes. MAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)

  26. Change From Baseline in Hematology Laboratory Test Results by Timepoint: Mean Corpuscular Hemoglobin. MAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)

  27. Change From Baseline in Hematology Laboratory Test Results by Timepoint: Red Blood Cell Count. MAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)

  28. Change From Baseline in Hematology Laboratory Test Results by Timepoint: Eosinophils. MAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)

  29. Change From Baseline in Hematology Laboratory Test Results by Timepoint: Monocytes. MAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)

  30. Change From Baseline in Hematology Laboratory Test Results by Timepoint: Thrombocytes. MAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)

  31. Change From Baseline in Hematology Laboratory Test Results by Timepoint: Basophils. MAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)

  32. Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Aspartate Aminotransferase. SAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)

  33. Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Total Protein. SAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)

  34. Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Gamma-GT. SAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value

    Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)

  35. Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Alkaline Phosphatase. SAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)

  36. Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Creatinine. SAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)

  37. Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Chloride. SAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)

  38. Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Total Bilirubin. SAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)

  39. Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Alanine Aminotransferase. SAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)

  40. Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Creatinine Kinase. SAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)

  41. Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Urea. SAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)

  42. Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Sodium. SAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)

  43. Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Potassium. SAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)

  44. Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Phosphate. SAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)

  45. Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Calcium (Corrected for Albumin). SAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)

  46. Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Uric Acid. SAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)

  47. Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Triiodothyronine (T3). SAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)

  48. Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Lipase. SAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)

  49. Change From Baseline in Chemistry Laboratory Test Results by Timepoint: (Fasting) Glucose. SAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)

  50. Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Human Serum Albumin. SAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)

  51. Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Cholesterol. SAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)

  52. Change From Baseline in Chemistry Laboratory Test Results by Timepoint: High Density Lipoproteins. SAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)

  53. Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Triglycerides. SAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)

  54. Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Low Density Lipoproteins. SAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)

  55. Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Bicarbonate. SAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)

  56. Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Thyroid-stimulating Hormone. SAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)

  57. Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Thyroxine (T4). SAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)

  58. Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Lactate. SAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)

  59. Change From Baseline in Chemistry Laboratory Test Results by Time Point: Total Protein. MAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline (pre-dose Day1), Day 3, Day 8, FU (one week after last dosing)

  60. Change From Baseline in Chemistry Laboratory Test Results by Time Point: Alkaline Phosphatase. MAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline, Day 3, Day 8, FU (one week after last dosing)

  61. Change From Baseline in Chemistry Laboratory Test Results by Time Point: Aspartate Aminotransferase. MAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline, Day 3, Day 8, FU (one week after last dosing)

  62. Change From Baseline in Chemistry Laboratory Test Results by Time Point: Creatine Kinase. MAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline, Day 3, Day 8, FU (one week after last dosing)

  63. Change From Baseline in Chemistry Laboratory Test Results by Time Point: Gamma GT. MAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline, Day 3, Day 8, FU (one week after last dosing)

  64. Change From Baseline in Chemistry Laboratory Test Results by Time Point: Total Bilirubin. MAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline, Day 3, Day 8, FU (one week after last dosing)

  65. Change From Baseline in Chemistry Laboratory Test Results by Time Point: Urea. MAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline, Day 3, Day 8, FU (one week after last dosing)

  66. Change From Baseline in Chemistry Laboratory Test Results by Time Point: Creatinine. MAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline, Day 3, Day 8, FU (one week after last dosing)

  67. Change From Baseline in Chemistry Laboratory Test Results by Time Point: Sodium. MAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline, Day 3, Day 8, FU (one week after last dosing)

  68. Change From Baseline in Chemistry Laboratory Test Results by Time Point: Potassium. MAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline, Day 3, Day 8, FU (one week after last dosing)

  69. Change From Baseline in Chemistry Laboratory Test Results by Time Point: Chloride. MAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline, Day 3, Day 8, FU (one week after last dosing)

  70. Change From Baseline in Chemistry Laboratory Test Results by Time Point: Calcium (Corrected for Albumin). MAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline, Day 3, Day 8, FU (one week after last dosing)

  71. Change From Baseline in Chemistry Laboratory Test Results by Time Point: Uric Acid. MAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline, Day 3, Day 8, FU (one week after last dosing)

  72. Change From Baseline in Chemistry Laboratory Test Results by Time Point: Lipase. MAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline, Day 3, Day 8, FU (one week after last dosing)

  73. Change From Baseline in Chemistry Laboratory Test Results by Time Point: Alanine Aminotransferase. MAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline, Day 3, Day 8, FU (one week after last dosing)

  74. Change From Baseline in Chemistry Laboratory Test Results by Time Point: Phosphate. MAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline, Day 3, Day 8, FU (one week after last dosing)

  75. Change From Baseline in Chemistry Laboratory Test Results by Time Point: Human Serum Albumin. MAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline, Day 3, Day 8, FU (one week after last dosing)

  76. Change From Baseline in Chemistry Laboratory Test Results by Time Point: Fasting Glucose. MAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline, Day 3, Day 8, FU (one week after last dosing)

  77. Change From Baseline in Chemistry Laboratory Test Results by Time Point: Cholesterol. MAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline, Day 3, Day 8, FU (one week after last dosing)

  78. Change From Baseline in Chemistry Laboratory Test Results by Time Point: Triglycerides. MAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline, Day 3, Day 8, FU (one week after last dosing)

  79. Change From Baseline in Chemistry Laboratory Test Results by Time Point: Low Density Lipoproteins. MAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline, Day 3, Day 8, FU (one week after last dosing)

  80. Change From Baseline in Chemistry Laboratory Test Results by Time Point: High Density Lipoproteins. MAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline, Day 3, Day 8, FU (one week after last dosing)

  81. Change From Baseline in Chemistry Laboratory Test Results by Time Point: Thyroid-stimulating Hormone. MAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline, Day 3, Day 8, FU (one week after last dosing)

  82. Change From Baseline in Chemistry Laboratory Test Results by Time Point: Trilodothyronine (T3). MAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline, Day 3, Day 8, FU (one week after last dosing)

  83. Change From Baseline in Chemistry Laboratory Test Results by Time Point: Thyroxine (T4). MAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline, Day 3, Day 8, FU (one week after last dosing)

  84. Change From Baseline in Chemistry Laboratory Test Results by Time Point: Bicarbonate. MAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline, Day 3, Day 8, FU (one week after last dosing)

  85. Change From Baseline in Chemistry Laboratory Test Results by Time Point: Lactate. MAD Group

    Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

    Time frame: Baseline, Day 3, Day 8, FU (one week after last dosing)

  86. Phospholipidosis

    Change from Day 1 to Day 7 in di-docosahexaenoyl (22:6)-bis(monoacylglycerol) phosphate (di-22:6-BMP) and normalized di-22:6-BMP (urine) - MAD

    Time frame: Day 1, Day 7

  87. MAD: Change From Baseline in ECG Results by Time Point: Corrected QT Interval According to Barret's Formaula (QTcB)

    The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation the average of the 3 recordings will be taken as baseline. Other ECG recordings will be singlet (one recording of at least 3 complexes) prior to dosing, or around the expected Cmax on Day 1 or 7 for the multiple- dose part.

    Time frame: Baseline (pre-dose Day 1), Day1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Follow-up

  88. MAD: Change From Baseline in ECG Results by Time Point: P Wave-Q Wave Interval (PQ Interval)

    The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation of the PQ interval the average of the 3 recordings will be taken as baseline.

    Time frame: Baseline (pre-dose Day 1), Day1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Follow-up

  89. MAD: Change From Baseline in ECG Results by Time Point: the Interval That Denotes Depolarization of the Ventricles, Between the Beginning of the Q Wave and the End of the S Wave (QRS Interval)

    The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation the average of the 3 recordings will be taken as baseline. Other ECG recordings will be singlet (one recording of at least 3 complexes) prior to dosing, or around the expected Cmax on Day 1 or 7 for the multiple- dose part.

    Time frame: Baseline (pre-dose Day 1), Day1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Follow-up

  90. MAD: Change From Baseline in ECG Results by Time Point: QT Interval

    The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation the average of the 3 recordings will be taken as baseline. Other ECG recordings will be singlet (one recording of at least 3 complexes) prior to dosing, or around the expected Cmax on Day 1 or 7 for the multiple- dose part.

    Time frame: Baseline (pre-dose Day 1), Day1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Follow-up

  91. SAD: Change From Baseline in ECG Results by Time Point: PQ Interval

    The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation the average of the 3 recordings will be taken as baseline.

    Time frame: Pre-dose, Day 1, Day 7

  92. SAD: Change From Baseline in ECG Results by Time Point: QRS Interval

    The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation the average of the 3 recordings will be taken as baseline.

    Time frame: Pre-dose, Day 1, Day 7

  93. SAD: Change From Baseline in ECG Results by Time Point: QT Interval

    The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation the average of the 3 recordings will be taken as baseline.

    Time frame: Pre-dose, Day 1, Day 7

  94. SAD: Change From Baseline in ECG Results by Time Point: QTcB Interval

    The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation the average of the 3 recordings will be taken as baseline.

    Time frame: Pre-dose, Day1, Day 7

  95. Terminal Elimination Half-life (T1/2) of KH176 Over 24 Hours: SAD

    Plasma concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.

    Time frame: Pre-dose (5 min before dosing) and 0.5, 1, 1.5, 2, 3, 6, 8, 12, and 24 hours post-dose

  96. Terminal Elimination Half-life (T1/2) of KH183: SAD

    Plasma concentrations of KH183 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food) , 300mg, 800mg, 2000mg b.i.d.

    Time frame: Pre-dose (5 min before dosing) and 0.5, 1, 1.5, 2, 3, 6, 8, 12, and 24 hours post-dose

  97. Maximum Concentration (Cmax) of KH176: SAD Group

    Plasma concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.

    Time frame: Pre-dose (5 min before dosing) and 0.5, 1, 1.5, 2, 3, 6, 8, 12, and 24 hours post-dose

  98. Maximum Concentration (Cmax) of KH183 Over 24 Hours: SAD

    Plasma concentrations of KH183 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food) , 300mg, 800mg, 2000mg b.i.d.

    Time frame: Pre-dose (5 min before dosing) and 0.5, 1, 1.5, 2, 3, 6, 8, 12, and 24 hours post-dose

  99. Maximum Concentration (Cmax) of KH183 (Active Metabolite of KH176): MAD Group

    Plasma concentrations of KH183 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.: Cmax was obtained directly from the concentration-time data.

    Time frame: Predose at Day 1, 2, 4, 7, and post-dose at Day 1 and Day 7 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours

  100. Maximum Concentration (Cmax) of KH176: MAD

    Plasma concentrations of KH176 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.

    Time frame: pre-dose at Day 1, 2, 4, 7, and post-dose at Day 1 and Day 7 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours

  101. Time to Maximum Concentration (Tmax) of KH176 Over 24 Hours: SAD

    Plasma concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.

    Time frame: Pre-dose (5 min before dosing) and 0.5, 1, 1.5, 2, 3, 6, 8, 12, and 24 hours post-dose

  102. Time to Reach Peak Plasma Concentration (Tmax) of KH183: SAD

    Plasma concentrations of KH183 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.

    Time frame: Pre-dose (5 min before dosing) and 0.5, 1, 1.5, 2, 3, 6, 8, 12, and 24 hours post-dose

  103. Time to Maximum Concentration (Tmax) of KH176 at Day 1, Day 7: MAD Group

    Plasma concentrations of KH176 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.

    Time frame: pre-dose at Day 1, 2, 4, 7, and post-dose at Day 1 and Day 7 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours

  104. Time to Maximum Concentration (Tmax) of KH183 (Active Metabolite of KH176): MAD Group

    Plasma concentrations of KH183 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.. tmax was obtained directly from the concentration-time data.

    Time frame: Predose at Day 1, 2, 4, 7, and post-dose at Day 1 and Day 7 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours

  105. Accumulation Factor (Racc) of KH176 Over 7 Days: MAD Group

    Plasma concentrations of KH176 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.. Racc was calculated as follows: AUCtau day 7/ AUCtau day 1.

    Time frame: Pre-dose at Day 1, 2, 4, 7, and post-dose at Day 1 and Day 7 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours

  106. Accumulation Factor (Racc) of KH183 (Active Metabolite of KH176): MAD Group

    Plasma concentrations of KH183 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.: Accumulation factor was calculated as follows: AUCtau day 7/ AUCtau day 1.

    Time frame: Predose at Day 1, 2, 4, 7, and post-dose at Day 1 and Day 7 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours

  107. Area Under the Plasma Concentration Versus Time Curve (AUClast) of KH183: SAD Group

    Plasma concentrations of KH183 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food) , 300mg, 800mg, 2000mg b.i.d.

    Time frame: Pre-dose (5 min before dosing) and 0.5, 1, 1.5, 2, 3, 6, 8, 12, and 24 hours post-dose

  108. Area Under the Plasma Concentration Versus Time Curve (AUClast) of KH176: SAD Group

    Plasma concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.

    Time frame: pre-dose (5 min before dosing) and 0.5, 1, 1.5, 2, 3, 6, 8, 12, and 24 hours post-dose

  109. Area Under the Plasma Concentration-time Curve (AUCtau) of KH176: MAD Group:

    Plasma concentrations of KH176 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.

    Time frame: Pre-dose at Day 1, 2, 4, 7, and post-dose at Day 1 and Day 7 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours

  110. Area Under the Plasma Concentration-time Curve During a Dose Interval (AUCtau) of KH183 (Active Metabolite of KH176): MAD Group

    Plasma concentrations of KH183 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.

    Time frame: Predose at Day 1, 2, 4, 7, and post-dose at Day 1 and Day 7 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours

  111. Area Under the Plasma Concentration-time Curve From Time Zero Until Infinity (AUCl0-inf) of KH183: SAD

    Plasma concentrations of KH183 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food) , 300mg, 800mg, 2000mg b.i.d.

    Time frame: Pre-dose (5 min before dosing) and 0.5, 1, 1.5, 2, 3, 6, 8, 12, and 24 hours post-dose

  112. Area Under the Plasma Concentration-time Curve From Time Zero Until Infinity (AUCl0-inf) of KH176: SAD

    Plasma concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food) , 300mg, 800mg, 2000mg b.i.d.

    Time frame: Pre-dose (5 min before dosing) and 0.5, 1, 1.5, 2, 3, 6, 8, 12, and 24 hours post-dose

  113. KH176: Percentage of Administered Dose Excreted in Urine: SAD

    Urine concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.

    Time frame: 24 hours post-dose

  114. KH183: Percentage of Administered Dose Excreted in Urine: SAD

    Urine concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.

    Time frame: 24 hours post-dose

  115. KH176 + KH183: Percentage of Administered Dose Excreted in Urine: SAD

    Urine concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.

    Time frame: 24 hours post-dose

  116. KH176: Percentage of Administered Dose Excreted in Urine: MAD

    Urine concentrations of KH176 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.

    Time frame: Day 7 post dose

  117. KH183: Percentage of Administered Dose Excreted in Urine: MAD

    Urine concentrations of KH183 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.

    Time frame: Post dose Day 7

  118. KH173 + KH183: Percentage of Administered Dose Excreted in Urine: MAD

    Urine concentrations of KH176 and KH183 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.

    Time frame: Day 7 Post dose

07

Results

Posted Nov 12, 2020

Participant flow

All studies were conducted at the Drug Research Unit Ghent. Participants agreed to stay in the Drug Research Unit during the first 24 h after dosing (SAD) and during Day 8 (MAD).

Participant flow — Overall Study
MilestoneSingle Ascending Group ISingle Ascending Group IIMultiple Ascending Group IIIMultiple Ascending Group IVMultiple Ascending Group VPlacebo
Started774446
Completed664446
Not completed110000
Withdrew: Withdrawal by subject110000

Outcome measures

PrimarySAD: Change From Baseline in ECG Results by Timepoint: Corrected QT Interval According to Fridericia's Formula (QTcF)

The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation of the corrected QT intervals the average of the 3 recordings will be taken as baseline. Other ECG recordings will be singlet (one recording of at least 3 complexes) prior to dosing. QTcF is calculated as the quotient between the QT interval in milliseconds and the cube root of the RR interval in seconds, according to Fridericia's formula.

Time frame:
Baseline, 1, 2, 4, 6, 8, 12, 24 hours, 7 day follow up
Reported as:
Mean · msec
SAD: Change From Baseline in ECG Results by Timepoint: Corrected QT Interval According to Fridericia's Formula (QTcF)
msecGroup I PlaceboGroup II PlaceboSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I Placebo + FoodGroup I 100mg + Food
Baseline (Pre-dose Day 1)386.2 ± 17.2395.0 ± 9.8385.8 ± 14.8399.3 ± 8.3390.3 ± 14.6393.5 ± 14.2386.5 ± 10.9385.3 ± 16.8369.0 ± 14.1386.5 ± 13.2
Change from baseline (BL)at 1h4.0 ± 2.8-2.0 ± 8.7-0.3 ± 3.8-3.5 ± 6.00.8 ± 4.00.8 ± 5.70.3 ± 7.628.8 ± 19.04.5 ± 19.15.8 ± 2.6
Change from BL at 2h0.5 ± 7.9-4.0 ± 6.6-1.8 ± 7.9-4.8 ± 6.1-4.8 ± 3.01.5 ± 6.07.8 ± 10.028.5 ± 14.12.5 ± 13.41.8 ± 5.3
Change from BL at 4h6.5 ± 9.4-2.2 ± 11.4-3.8 ± 3.3-4.3 ± 6.21.0 ± 5.73.8 ± 12.33.3 ± 7.226.0 ± 8.78.5 ± 17.70.3 ± 3.9
Change from BL at 6h6.2 ± 3.6-2.7 ± 6.04.3 ± 6.3-4.0 ± 7.3-1.0 ± 8.35.8 ± 8.15.5 ± 2.526.0 ± 7.98.5 ± 12.06.0 ± 5.0
Change from BL at 8h-0.8 ± 7.3-7.2 ± 4.0-5.5 ± 7.4-1.8 ± 9.24.3 ± 10.3-1.8 ± 9.00.8 ± 7.523.3 ± 12.3-2.5 ± 13.40.5 ± 5.4
Change from BL at 12h1.8 ± 6.7-5.2 ± 4.8-1.8 ± 2.6-7.3 ± 6.80.0 ± 4.70.0 ± 8.08.0 ± 0.819.3 ± 11.15.5 ± 7.83.3 ± 6.2
Change from BL at 24h5.3 ± 12.4-7.5 ± 9.3-4.0 ± 7.3-4.8 ± 5.60.3 ± 6.2-4.3 ± 6.50.3 ± 9.711.3 ± 4.7-1.0 ± 8.5-3.8 ± 4.0
Change from BL at FU-0.3 ± 12.42.8 ± 7.9-1.3 ± 10.82.8 ± 8.02.8 ± 13.15.0 ± 6.1-5.0 ± 3.23.3 ± 7.65.5 ± 10.66.5 ± 13.0
PrimaryPharmacodynamics of KH176

Change from baseline in biochemistry related to Oxidative Phosphorylation (OXPHOS) (glutathione, lactate); MAD group

Time frame:
Day 1, day 7
Reported as:
Mean · ratio GSH/GSSG
Pharmacodynamics of KH176
ratio GSH/GSSGMAD Group IIIMAD Group IVMAD Group VPlacebo
Ox glutathione (GSH)/Red Glutathati(GSSG) Day 1-0h872 ± 5322083 ± 6742275 ± 7921584 ± 491
GSH/GSSG Day 7-0h919 ± 1961923 ± 4331918 ± 10071694 ± 572
GSH/GSSG Day 7-3h779 ± 872045 ± 3381935 ± 6991712 ± 465
GSH/GSSG Day 7-6h1040 ± 3352113 ± 6871993 ± 8631718 ± 542
GSH/GSSG Day 7-12h1361 ± 6061893 ± 2791875 ± 6971680 ± 657
PrimaryRelationship to Study Drug and Severity of Treatment-emergent Adverse Events
Time frame:
4 months
Reported as:
Number · TEAE
Relationship to Study Drug and Severity of Treatment-emergent Adverse Events
TEAEGroup I PlaceboGroup II PlaceboSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I Placebo + FoodGroup I 100mg + FoodMAD Group III 200mgMAD Group IV 400mgMAD Group V 800mgPlacebo
TEAE52257102811961417
Serious TEAE00000000000000
Not related TEAE40026000111133
Unlikely related02230000001121
Possibly related100010030074913
Related000001025000000
PrimaryChange From Baseline in Hematology Laboratory Test Results by Timepoint: Red Blood Cell Count. SAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline (pre-dose Day 1), 24h post dose, FU (7 days after last dosing)
Reported as:
Mean · cells 10^6/µL
Change From Baseline in Hematology Laboratory Test Results by Timepoint: Red Blood Cell Count. SAD Group
cells 10^6/µLGroup I PlaceboGroup II PlaceboSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I Placebo + FoodGroup I 100mg + Food
Baseline (pre-dose Day 1)4.947 ± 0.4884.933 ± 0.3074.793 ± 0.4555.030 ± 0.4584.953 ± 0.2475.137 ± 0.3934.973 ± 0.1414.623 ± 0.3955.095 ± 0.1204.985 ± 0.343
Change from BL at 24h0.200 ± 0.4950.095 ± 0.2600.063 ± 0.0850.188 ± 0.1530.170 ± 0.2500.065 ± 0.1970.173 ± 0.2000.325 ± 0.1850.185 ± 0.0640.115 ± 0.208
Change from BL at FU0.003 ± 0.215-0.013 ± 0.1490.185 ± 0.104-0.052 ± 0.1830.083 ± 0.127-0.147 ± 0.041-0.053 ± 0.2090.125 ± 0.182-0.150 ± 0.3390.050 ± 0.211
PrimaryChange From Baseline in Hematology Laboratory Test Results by Timepoint: Erythrocyte Sedimentation Rate (SAD Group)
Time frame:
Baseline (pre-dose Day1), 24h post dose, FU (7 days after last dosing)
Reported as:
Mean · mm/hr
Change From Baseline in Hematology Laboratory Test Results by Timepoint: Erythrocyte Sedimentation Rate (SAD Group)
mm/hrGroup I PlaceboGroup II PlaceboSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I Placebo + FoodGroup I 100mg + Food
Baseline2.3 ± 1.42.8 ± 2.11.3 ± 0.51.8 ± 1.02.0 ± 1.43.0 ± 4.07.3 ± 8.54.0 ± 3.25.0 ± 2.82.5 ± 3.0
Change from BL at 24h0.5 ± 0.50.3 ± 1.00.0 ± 0.01.0 ± 0.80.0 ± 0.80.3 ± 1.00.3 ± 0.63.0 ± 3.6-0.5 ± 0.71.0 ± 2.0
Change from BL at FU0.3 ± 1.20.3 ± 1.50.8 ± 1.00.5 ± 1.70.5 ± 1.70.0 ± 0.0-2.3 ± 6.80.5 ± 1.00.0 ± 0.00.0 ± 0.0
PrimaryChange From Baseline in Hematology Laboratory Test Results by Timepoint: Erythrocyte Sedimentation Rate MAD Group
Time frame:
Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days after last dosing)
Reported as:
Mean · mm/hr
Change From Baseline in Hematology Laboratory Test Results by Timepoint: Erythrocyte Sedimentation Rate MAD Group
mm/hrMAD Group IIIMAD Group IVMAD Group VPlacebo
Baseline (pre-dose Day 1)4.0 ± 2.43.0 ± 1.82.0 ± 1.42.7 ± 1.8
Change from BL at Day 32.0 ± 3.50.8 ± 0.50.5 ± 0.60.8 ± 1.7
Change from BL at Day 84.8 ± 5.70.8 ± 2.22.5 ± 1.70.3 ± 1.4
Change from BL at FU5.0 ± 8.21.3 ± 1.31.0 ± 0.82.2 ± 3.5
PrimaryChange From Baseline in Hematology Laboratory Test Results by Timepoint: Hematocrit SAD Group

Hematocrit is a measure of the ratio of red blood cells (RBCs) in the blood by volume. Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline (pre-dose Day 1), 24 h postdose, FU (7 days after last dosing)
Reported as:
Mean · %red cells to the volume of whole blood.
Change From Baseline in Hematology Laboratory Test Results by Timepoint: Hematocrit SAD Group
%red cells to the volume of whole blood.Group I PlaceboGroup II PlaceboSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I Placebo + FoodGroup I 100mg + Food
Baseline (pre-dose Day 1)43.77 ± 3.3543.13 ± 2.7943.10 ± 3.4644.38 ± 3.2842.98 ± 1.4144.35 ± 2.8844.05 ± 3.1741.35 ± 1.6844.35 ± 2.3342.53 ± 1.50
Change from BL at 24h0.53 ± 1.280.60 ± 2.100.75 ± 0.911.95 ± 1.411.42 ± 2.121.03 ± 2.111.33 ± 1.802.33 ± 1.871.90 ± 0.280.68 ± 1.92
Change from BL at FU-0.43 ± 1.70-0.65 ± 1.370.85 ± 1.45-0.93 ± 1.910.10 ± 1.66-2.02 ± 0.54-1.15 ± 2.170.07 ± 1.41-0.65 ± 3.040.55 ± 2.20
PrimaryChange From Baseline in Hematology Laboratory Test Results by Timepoint: Mean Corpuscular Haemoglobin. SAD

Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline (pre-dose Day 1), 24 h post dose, FU (7 days after last dosing)
Reported as:
Mean · pg/cell
Change From Baseline in Hematology Laboratory Test Results by Timepoint: Mean Corpuscular Haemoglobin. SAD
pg/cellGroup I PlaceboGroup II PlaceboSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I Placebo + FoodGroup I 100mg + Food
Baseline (pre-dose Day 1)30.32 ± 1.8329.70 ± 0.9830.78 ± 1.7130.38 ± 0.4930.00 ± 1.7529.63 ± 0.6830.28 ± 1.2629.80 ± 1.1630.25 ± 1.7729.65 ± 2.13
Change from BL at 24h - Day 10.08 ± 0.340.23 ± 0.590.17 ± 0.26-0.08 ± 0.26-0.15 ± 0.13-0.60 ± 0.80-0.25 ± 0.370.33 ± 0.410.25 ± 0.640.20 ± 0.34
Change from BL at FU-0.22 ± 0.150.05 ± 0.46-0.28 ± 0.57-0.23 ± 0.51-0.42 ± 0.37-0.28 ± 0.21-0.58 ± 0.220.12 ± 0.39-0.15 ± 0.35-0.08 ± 0.15
PrimaryChange From Baseline in Hematology Laboratory Test Results by Timepoint: Mean Corpuscular Hemoglobin Concentration - SAD

Erythrocyte mean corpuscular hemoglobin concentration (MCHC) is a measure of the average concentration of hemoglobin per red blood cell. Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline (pre-dose Day 1), 24 h post dose, FU (7 days after last dosing)
Reported as:
Mean · g/dL RBC
Change From Baseline in Hematology Laboratory Test Results by Timepoint: Mean Corpuscular Hemoglobin Concentration - SAD
g/dL RBCGroup I PlaceboGroup II PlaceboSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I Placebo + FoodGroup I 100mg + Food
Baseline (pre-dose Day 1)34.15 ± 0.3433.98 ± 1.0134.18 ± 0.4634.38 ± 0.8434.53 ± 0.4534.33 ± 1.0734.20 ± 0.6533.25 ± 0.7134.70 ± 0.5734.68 ± 0.99
Change from BL at 24h - Day 1-0.07 ± 0.320.43 ± 0.420.00 ± 0.35-0.27 ± 0.39-0.17 ± 0.15-1.05 ± 0.87-0.20 ± 0.420.82 ± 0.290.10 ± 0.570.45 ± 0.68
Change from BL at FU0.17 ± 0.620.47 ± 0.420.27 ± 0.540.18 ± 0.60-0.05 ± 0.640.30 ± 0.48-0.13 ± 0.611.00 ± 0.12-0.60 ± 0.28-0.20 ± 0.42
PrimaryChange From Baseline in Hematology Laboratory Test Results by Timepoint: Mean Corpuscular Volume - SAD

Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline (pre-dose Day 1), 24 h post dose, FU (7 days after last dosing)
Reported as:
Mean · fL
Change From Baseline in Hematology Laboratory Test Results by Timepoint: Mean Corpuscular Volume - SAD
fLGroup I PlaceboGroup II PlaceboSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I Placebo + FoodGroup I 100mg + Food
Baseline (pre-dose Day 1)88.75 ± 5.3687.52 ± 3.7190.15 ± 5.7388.35 ± 2.8886.93 ± 4.7586.42 ± 2.8388.55 ± 4.5789.73 ± 4.2487.10 ± 6.6585.48 ± 4.36
Change from BL at 24h0.45 ± 0.85-0.38 ± 1.090.35 ± 0.370.48 ± 0.410.00 ± 0.080.85 ± 0.73-0.27 ± 0.21-1.33 ± 0.720.60 ± 0.28-0.55 ± 0.79
Change from BL at FU-1.10 ± 1.85-1.03 ± 0.46-1.68 ± 0.90-0.92 ± 1.28-1.25 ± 1.54-1.52 ± 0.69-1.45 ± 1.02-2.30 ± 1.001.10 ± 0.280.20 ± 0.81
PrimaryMAD: Change From Baseline in ECG Results by Time Point: QTcF

The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation of the corrected QT intervals the average of the 3 recordings will be taken as baseline. Other ECG recordings will be singlet (one recording of at least 3 complexes) prior to dosing, or around the expected Cmax on Day 1 or 7 for the multiple-dose part. QTcF is calculated as the quotient between the QT interval in milliseconds and the cube root of the RR interval in seconds, according to Fridericia's formula.

Time frame:
Baseline, Day1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7
Reported as:
Mean · msec
MAD: Change From Baseline in ECG Results by Time Point: QTcF
msecMAD Group IIIMAD Group IVMAD Group VPlacebo
Baseline (Pre-dose Day 1)397.3 ± 18.4384.3 ± 21.7388.5 ± 4.7393.0 ± 18.8
Change from BL at 2h - Day 10.5 ± 7.55.5 ± 8.17.3 ± 7.01.7 ± 5.3
Change from BL at 24h - Day 1-4.3 ± 6.60.5 ± 5.73.3 ± 13.6-4.8 ± 3.7
Change from BL Day 7 at 1h - Day 7-1.3 ± 10.2-3.0 ± 3.3-6.5 ± 8.1-2.2 ± 2.7
Change from BL Day 7 at 2h - Day 7-3.5 ± 2.5-0.3 ± 8.2-0.8 ± 3.2-0.3 ± 10.1
Change from BL Day 7 at 4h-7.5 ± 4.7-3.8 ± 3.5-5.8 ± 7.73.0 ± 11.2
Change from BL Day 7 BL at 6h - Day 7-1.8 ± 7.32.0 ± 4.7-7.3 ± 1.9-0.5 ± 21.0
Change from BL Day 7 at 8h - Day 7-11.3 ± 3.2-3.8 ± 6.9-11.0 ± 5.30.8 ± 3.9
Change from BL Day 7 at 12h - Day 7-4.3 ± 4.6-5.0 ± 3.5-10.0 ± 4.71.7 ± 6.0
Change from BL at pre-dose Day 2-4.3 ± 6.60.5 ± 5.73.3 ± 13.6-4.8 ± 3.7
Change from BL at pre-dose Day 30.5 ± 8.62.8 ± 6.410.5 ± 17.2-7.5 ± 6.8
Change from BL at pre-dose Day 42.5 ± 14.60.5 ± 13.67.3 ± 10.2-6.7 ± 8.4
Change from BL at pre-dose Day 56.0 ± 13.32.5 ± 7.210.8 ± 6.7-5.3 ± 7.3
Change from BL at pre-dose Day 6-1.3 ± 12.5-1.5 ± 6.27.8 ± 8.0-8.2 ± 11.8
Change from BL at pre-dose Day 7-1.0 ± 11.93.0 ± 9.513.5 ± 8.7-8.8 ± 9.2
Change from BL at FU-2.3 ± 5.04.0 ± 6.3-0.5 ± 14.46.7 ± 14.1
PrimaryChange From Baseline in Hematology Laboratory Test Results by Timepoint: White Blood Cell Count. SAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline (pre-dose Day 1), 24h post dose, FU (7 days after last dosing)
Reported as:
Mean · cells 10^3/µL
Change From Baseline in Hematology Laboratory Test Results by Timepoint: White Blood Cell Count. SAD Group
cells 10^3/µLGroup I PlaceboGroup II PlaceboSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I Placebo + FoodGroup I 100mg + Food
Baseline (pre-dose Day 1)4.435 ± 0.5264.773 ± 0.5484.313 ± 0.4184.863 ± 0.3724.395 ± 0.6944.475 ± 0.7334.853 ± 0.3725.118 ± 0.6475.815 ± 2.0725.535 ± 1.467
Change from BL at 24h0.343 ± 0.525-0.057 ± 0.359-0.033 ± 0.3170.160 ± 0.3290.257 ± 0.5290.160 ± 0.7530.528 ± 0.3240.655 ± 0.6660.220 ± 0.721-0.280 ± 0.555
Change from BL at FU0.258 ± 0.309-0.203 ± 0.6620.288 ± 0.211-0.073 ± 0.3670.395 ± 0.617-0.287 ± 0.6180.215 ± 0.266-0.320 ± 0.592-0.560 ± 1.202-0.745 ± 1.535
PrimaryChange From Baseline in Hematology Laboratory Test Results by Timepoint: Lymphocytes. SAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Reported as:
Mean · cells/µL
Change From Baseline in Hematology Laboratory Test Results by Timepoint: Lymphocytes. SAD Group
cells/µLGroup I PlaceboGroup II PlaceboSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I Placebo + FoodGroup I 100mg + Food
Baseline (pre-dose Day 1)1570.0 ± 227.01748.3 ± 441.11655.0 ± 200.41862.5 ± 548.21485.0 ± 169.21570.0 ± 273.11550.0 ± 275.31497.5 ± 707.62260.0 ± 975.81640.0 ± 243.2
Change from BL at 24h-13.3 ± 223.4-16.7 ± 347.3-45.0 ± 192.8-172.5 ± 227.1-27.5 ± 58.092.5 ± 225.6287.5 ± 353.737.5 ± 159.9-135.0 ± 261.6-70.0 ± 177.6
Change from BL at FU86.7 ± 265.3-45.0 ± 253.3180.0 ± 186.5-92.5 ± 315.7127.5 ± 425.2-32.5 ± 174.6135.0 ± 294.2-7.5 ± 244.0-190.0 ± 410.1-27.5 ± 125.8
PrimaryChange From Baseline in Hematology Laboratory Test Results by Timepoint: Neutrophils. SAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline (pre-dose Day 1), 24h post dose, FU (7 days after last dosing)
Reported as:
Mean · cells/µL
Change From Baseline in Hematology Laboratory Test Results by Timepoint: Neutrophils. SAD Group
cells/µLGroup I PlaceboGroup II PlaceboSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I Placebo + FoodGroup I 100mg + Food
Baseline (pre-dose Day 1)2276.7 ± 551.22296.7 ± 658.72117.5 ± 369.22365.0 ± 820.82380.0 ± 679.02197.5 ± 835.92565.0 ± 462.62360.0 ± 438.12280.0 ± 169.73192.5 ± 1523.9
Change from BL at 24h356.7 ± 336.998.3 ± 171.27.5 ± 196.7410.0 ± 593.0272.5 ± 419.1165.0 ± 335.5285.0 ± 155.0440.0 ± 601.5445.0 ± 459.6-122.5 ± 584.3
Change from BL at FU205.0 ± 161.8-16.7 ± 335.490.0 ± 183.5107.5 ± 252.1255.0 ± 519.0-167.5 ± 480.7-12.5 ± 203.5-382.5 ± 232.9-205.0 ± 445.5-557.5 ± 1326.2
PrimaryChange From Baseline in Hematology Laboratory Test Results by Timepoint: Hematocrit MAD Group

Hematocrit is a measure of the ratio of red blood cells (RBCs) in the blood by volume. Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value

Time frame:
Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)
Reported as:
Mean · % of red cells to volume of whole blood.
Change From Baseline in Hematology Laboratory Test Results by Timepoint: Hematocrit MAD Group
% of red cells to volume of whole blood.MAD Group IIIMAD Group IVMAD Group VPlacebo
Baseline39.93 ± 1.2043.40 ± 3.5145.10 ± 1.3343.30 ± 1.95
Change from BL at Day 32.67 ± 1.941.17 ± 1.690.13 ± 0.451.70 ± 1.91
Change from BL at Day 83.30 ± 1.241.22 ± 3.260.10 ± 1.221.93 ± 2.69
Change from BL at FU0.92 ± 1.06-0.10 ± 3.26-1.05 ± 0.64-0.75 ± 2.32
PrimaryChange From Baseline in Hematology Laboratory Test Results by Timepoint: Eosinophils. SAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline (pre-dose Day 1), 24h post dose, FU (7 days after last dosing)
Reported as:
Mean · cells/µL
Change From Baseline in Hematology Laboratory Test Results by Timepoint: Eosinophils. SAD Group
cells/µLGroup I PlaceboGroup II PlaceboSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I Placebo + FoodGroup I 100mg + Food
Baseline (pre-dose Day 1)115.0 ± 50.1191.7 ± 109.4110.0 ± 49.7137.5 ± 83.4112.5 ± 36.9200.0 ± 78.7245.0 ± 233.6110.0 ± 71.6650.0 ± 792.0152.5 ± 81.0
Change from BL at 24h-5.0 ± 16.4-50.0 ± 40.5-17.5 ± 9.6-22.5 ± 42.7-15.0 ± 12.9-37.5 ± 47.9-25.0 ± 33.2-25.0 ± 26.5-25.0 ± 7.1-30.0 ± 47.6
Change from BL at FU-13.3 ± 16.3-58.3 ± 93.5-17.5 ± 25.0-12.5 ± 43.5-2.5 ± 18.9-42.5 ± 61.377.5 ± 201.6-20.0 ± 18.3-125.0 ± 205.1-42.5 ± 42.7
PrimaryChange From Baseline in Hematology Laboratory Test Results by Timepoint: Thrombocytes. SAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline (pre-dose Day 1), 24h, FU (7 days post-dose)
Reported as:
Mean · cells 10^3/µL
Change From Baseline in Hematology Laboratory Test Results by Timepoint: Thrombocytes. SAD Group
cells 10^3/µLGroup I PlaceboGroup II PlaceboSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I Placebo + FoodGroup I 100mg + Food
Baseline (pre-dose Day 1)209.5 ± 45.9204.0 ± 15.7193.0 ± 31.9223.0 ± 21.6215.8 ± 64.0203.8 ± 7.0202.3 ± 54.5160.1 ± 100.8204.5 ± 67.2215.8 ± 55.6
Change from BL at 24h0.0 ± 9.74.8 ± 6.18.5 ± 12.42.3 ± 12.83.8 ± 20.3-14.5 ± 29.722.3 ± 13.523.0 ± 22.84.0 ± 7.10.3 ± 9.0
Change from BL at FU11.8 ± 14.022.5 ± 15.723.8 ± 7.48.5 ± 24.316.3 ± 14.57.3 ± 7.915.8 ± 14.321.5 ± 22.41.0 ± 15.616.3 ± 12.5
PrimaryChange From Baseline in Hematology Laboratory Test Results by Timepoint: Basophils. SAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value ateach timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline (pre-dose Day 1), 24h post dose, FU (7 days post-dose)
Reported as:
Mean · cells/µL
Change From Baseline in Hematology Laboratory Test Results by Timepoint: Basophils. SAD Group
cells/µLGroup I PlaceboGroup II PlaceboSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I Placebo + FoodGroup I 100mg + Food
Baseline (pre-dose Day 1)23.3 ± 5.225.0 ± 10.515.0 ± 5.830.0 ± 18.315.0 ± 10.032.5 ± 15.020.0 ± 11.522.5 ± 5.065.0 ± 63.625.0 ± 17.3
Change from BL at 24h-5.0 ± 8.40.0 ± 8.92.5 ± 5.0-7.5 ± 9.60.0 ± 0.0-5.0 ± 10.02.5 ± 5.05.0 ± 5.8-20.0 ± 14.1-2.5 ± 9.6
Change from BL at FU0.0 ± 12.6-1.7 ± 7.55.0 ± 5.8-5.0 ± 10.07.5 ± 9.6-5.0 ± 12.920.0 ± 21.60.0 ± 8.2-15.0 ± 21.2-2.5 ± 5.0
PrimaryChange From Baseline in Hematology Laboratory Test Results by Timepoint: Monocytes. SAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline (pre-dose Day 1), 24h post dose, FU (7 days post-dose)
Reported as:
Mean · cells/µL
Change From Baseline in Hematology Laboratory Test Results by Timepoint: Monocytes. SAD Group
cells/µLGroup I PlaceboGroup II PlaceboSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I Placebo + FoodGroup I 100mg + Food
Baseline (pre-dose Day 1)445.0 ± 78.2496.7 ± 71.7407.5 ± 79.3455.0 ± 81.9397.5 ± 133.0467.5 ± 98.8462.5 ± 147.1470.0 ± 87.6550.0 ± 70.7512.5 ± 133.5
Change from BL at 24h1.7 ± 46.7-81.7 ± 54.920.0 ± 78.3-45.0 ± 19.320.0 ± 122.7-62.5 ± 185.5-25.0 ± 112.42.5 ± 56.8-45.0 ± 21.2-55.0 ± 70.5
Change from BL at FU-21.7 ± 91.5-78.3 ± 74.930.0 ± 136.4-70.0 ± 94.95.0 ± 128.2-42.5 ± 86.60.0 ± 94.9-47.5 ± 63.4-20.0 ± 127.3-110.0 ± 128.3
PrimaryChange From Baseline in Hematology Laboratory Test Results by Timepoint: Mean Corpuscular Volume. MAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)
Reported as:
Mean · fL
Change From Baseline in Hematology Laboratory Test Results by Timepoint: Mean Corpuscular Volume. MAD Group
fLMAD Group IIIMAD Group IVMAD Group VPlacebo
Baseline (pre-dose Day 1)87.00 ± 0.6289.32 ± 2.7386.43 ± 1.2989.02 ± 2.93
Change from BL at Day 3-0.05 ± 0.400.52 ± 1.150.55 ± 0.710.40 ± 1.08
Change from BL at Day 8-0.10 ± 1.30-0.43 ± 0.280.32 ± 0.900.28 ± 0.95
Change from BL at FU0.60 ± 0.74-0.55 ± 0.731.22 ± 1.310.65 ± 0.77
PrimaryChange From Baseline in Hematology Laboratory Test Results by Timepoint: Hemoglobin. MAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)
Reported as:
Mean · g/dL
Change From Baseline in Hematology Laboratory Test Results by Timepoint: Hemoglobin. MAD Group
g/dLMAD Group IIIMAD Group IVMAD Group VPlacebo
Baseline (pre-dose Day 1)13.68 ± 0.5915.23 ± 1.3815.68 ± 0.6414.82 ± 0.67
Change from BL at Day 31.05 ± 0.660.42 ± 0.740.17 ± 0.220.62 ± 0.50
Change from BL at Day 81.35 ± 0.370.55 ± 1.220.27 ± 0.600.75 ± 0.83
Change from BL at FU0.30 ± 0.49-0.05 ± 1.11-0.38 ± 0.47-0.35 ± 0.63
PrimaryChange From Baseline in Hematology Laboratory Test Results by Timepoint: White Blood Cell Count. MAD

Blood samples were collected from participants at the indicated time points for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each time point are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)
Reported as:
Mean · cells 10^3/µL
Change From Baseline in Hematology Laboratory Test Results by Timepoint: White Blood Cell Count. MAD
cells 10^3/µLMAD Group IIIMAD Group IVMAD Group VPlacebo
Baseline (pre-dose Day 1)5.463 ± 0.5794.753 ± 0.4105.378 ± 1.2214.583 ± 0.487
Change from BL at Day 3-0.435 ± 0.6310.480 ± 0.7870.895 ± 0.9400.277 ± 0.932
Change from BL at Day 80.223 ± 2.2370.480 ± 0.2520.795 ± 0.1780.563 ± 0.983
Change from BL at FU0.060 ± 2.5190.230 ± 0.8701.340 ± 0.546-0.140 ± 0.930
PrimaryChange From Baseline in Hematology Laboratory Test Results by Timepoint: Neutrophils. MAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)
Reported as:
Mean · cells/µL
Change From Baseline in Hematology Laboratory Test Results by Timepoint: Neutrophils. MAD Group
cells/µLMAD Group IIIMAD Group IVMAD Group VPlacebo
Baseline (pre-dose Day 1)3077.5 ± 569.52602.5 ± 582.42935.0 ± 966.62483.3 ± 583.6
Change from BL at Day 3-567.5 ± 667.9350.0 ± 602.4437.5 ± 505.381.7 ± 540.7
Change from BL at Day 8105.0 ± 2079.7312.5 ± 355.1537.5 ± 174.6261.0 ± 634.9
Change from BL at FU185.0 ± 2317.4177.5 ± 827.71010.0 ± 622.7-75.0 ± 532.1
PrimaryChange From Baseline in Hematology Laboratory Test Results by Timepoint: Mean Corpuscular Haemoglobin Concentration. MAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)
Reported as:
Mean · g/dL RBC
Change From Baseline in Hematology Laboratory Test Results by Timepoint: Mean Corpuscular Haemoglobin Concentration. MAD Group
g/dL RBCMAD Group IIIMAD Group IVMAD Group VPlacebo
Baseline (pre-dose Day 1)34.28 ± 1.0835.05 ± 0.3734.75 ± 0.6234.23 ± 0.37
Change from BL at Day 30.30 ± 0.220.05 ± 0.620.30 ± 0.390.08 ± 0.48
Change from BL at Day 80.47 ± 0.430.25 ± 0.260.50 ± 0.440.17 ± 0.38
Change from BL at FU-0.08 ± 0.330.00 ± 0.270.00 ± 0.65-0.22 ± 0.44
PrimaryChange From Baseline in Hematology Laboratory Test Results by Timepoint: Lymphocytes. MAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)
Reported as:
Mean · cells/µL
Change From Baseline in Hematology Laboratory Test Results by Timepoint: Lymphocytes. MAD Group
cells/µLMAD Group IIIMAD Group IVMAD Group VPlacebo
Baseline (pre-dose Day 1)1627.5 ± 656.01498.5 ± 125.11750.0 ± 187.41508.3 ± 317.1
Change from BL at Day 387.5 ± 177.8159.0 ± 188.6390.0 ± 297.4215.0 ± 372.3
Change from BL at Day 812.5 ± 378.5124.0 ± 148.8237.5 ± 208.1283.3 ± 402.6
Change from BL at FU-55.0 ± 257.539.0 ± 382.3262.5 ± 220.25.0 ± 465.9
PrimaryChange From Baseline in Hematology Laboratory Test Results by Timepoint: Mean Corpuscular Hemoglobin. MAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)
Reported as:
Mean · pg/cell
Change From Baseline in Hematology Laboratory Test Results by Timepoint: Mean Corpuscular Hemoglobin. MAD Group
pg/cellMAD Group IIIMAD Group IVMAD Group VPlacebo
Baseline (pre-dose Day 1)29.80 ± 0.9131.33 ± 1.2430.03 ± 0.4930.47 ± 0.97
Change from BL at Day 30.25 ± 0.130.23 ± 0.390.45 ± 0.260.20 ± 0.25
Change from BL at Day 80.40 ± 0.400.12 ± 0.220.57 ± 0.620.25 ± 0.33
Change from BL at FU0.15 ± 0.47-0.20 ± 0.080.40 ± 0.410.02 ± 0.25
PrimaryChange From Baseline in Hematology Laboratory Test Results by Timepoint: Red Blood Cell Count. MAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)
Reported as:
Mean · cells 10^6/µL
Change From Baseline in Hematology Laboratory Test Results by Timepoint: Red Blood Cell Count. MAD Group
cells 10^6/µLMAD Group IIIMAD Group IVMAD Group VPlacebo
Baseline (pre-dose Day 1)4.588 ± 0.1084.858 ± 0.3805.217 ± 0.1384.873 ± 0.360
Change from BL at Day 30.313 ± 0.2340.100 ± 0.193-0.017 ± 0.0600.167 ± 0.196
Change from BL at Day 80.385 ± 0.1390.160 ± 0.362-0.007 ± 0.1440.198 ± 0.249
Change from BL at FU0.075 ± 0.0990.020 ± 0.350-0.192 ± 0.145-0.120 ± 0.237
PrimaryChange From Baseline in Hematology Laboratory Test Results by Timepoint: Eosinophils. MAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)
Reported as:
Mean · cells/µL
Change From Baseline in Hematology Laboratory Test Results by Timepoint: Eosinophils. MAD Group
cells/µLMAD Group IIIMAD Group IVMAD Group VPlacebo
Baseline (pre-dose Day 1)212.5 ± 79.3183.5 ± 84.6127.5 ± 45.7141.7 ± 96.2
Change from BL at Day 3-40.0 ± 52.3-31.0 ± 53.27.5 ± 20.6-28.3 ± 43.6
Change from BL at Day 8-47.5 ± 87.3-28.5 ± 66.0-10.0 ± 27.1-22.7 ± 56.4
Change from BL at FU-27.5 ± 131.831.5 ± 26.5-17.5 ± 27.5-45.0 ± 76.4
PrimaryChange From Baseline in Hematology Laboratory Test Results by Timepoint: Monocytes. MAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)
Reported as:
Mean · cells/µL
Change From Baseline in Hematology Laboratory Test Results by Timepoint: Monocytes. MAD Group
cells/µLMAD Group IIIMAD Group IVMAD Group VPlacebo
Baseline (pre-dose Day 1)505.0 ± 44.3424.0 ± 140.9530.0 ± 134.9418.3 ± 61.5
Change from BL at Day 375.0 ± 151.5-11.5 ± 142.657.5 ± 115.01.7 ± 64.3
Change from BL at Day 8137.5 ± 374.676.0 ± 95.327.5 ± 42.724.3 ± 53.1
Change from BL at FU-52.5 ± 176.7-21.5 ± 140.582.5 ± 76.8-43.3 ± 85.0
PrimaryChange From Baseline in Hematology Laboratory Test Results by Timepoint: Thrombocytes. MAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)
Reported as:
Mean · cells 10^3/µL
Change From Baseline in Hematology Laboratory Test Results by Timepoint: Thrombocytes. MAD Group
cells 10^3/µLMAD Group IIIMAD Group IVMAD Group VPlacebo
Baseline (pre-dose Day 1)207.3 ± 24.6211.5 ± 41.2199.8 ± 25.6206.7 ± 48.1
Change from BL at Day 315.5 ± 14.517.5 ± 9.527.5 ± 8.417.3 ± 15.1
Change from BL at Day 844.8 ± 37.64.8 ± 22.331.3 ± 13.929.5 ± 12.5
Change from BL at FU63.8 ± 41.35.5 ± 21.933.8 ± 20.021.7 ± 10.7
PrimaryChange From Baseline in Hematology Laboratory Test Results by Timepoint: Basophils. MAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline (pre-dose Day 1), Day 3, Day 8, FU (7 days post dose)
Reported as:
Mean · cells/µL
Change From Baseline in Hematology Laboratory Test Results by Timepoint: Basophils. MAD Group
cells/µLMAD Group IIIMAD Group IVMAD Group VPlacebo
Baseline (pre-dose Day 1)30.0 ± 8.234.0 ± 10.820.0 ± 11.523.3 ± 10.3
Change from BL at Day 37.5 ± 17.18.5 ± 17.42.5 ± 5.03.3 ± 8.2
Change from BL at Day 812.5 ± 20.6-6.5 ± 17.05.0 ± 12.94.0 ± 14.7
Change from BL at FU7.5 ± 15.01.0 ± 6.62.5 ± 12.65.0 ± 18.7
PrimaryChange From Baseline in Chemistry Laboratory Test Results by Timepoint: Aspartate Aminotransferase. SAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Reported as:
Mean · U/L
Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Aspartate Aminotransferase. SAD Group
U/LGroup I PlaceboGroup II PlaceboSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I Placebo + FoodGroup I 100mg + Food
Baseline (pre-dose Day 1)20.5 ± 5.916.8 ± 2.719.3 ± 4.317.5 ± 3.818.3 ± 9.220.8 ± 4.418.8 ± 6.117.0 ± 2.919.5 ± 2.118.5 ± 4.8
Change from BL at 24h-2.7 ± 1.20.3 ± 2.1-0.5 ± 1.31.8 ± 3.0-2.5 ± 4.7-0.3 ± 1.0-1.0 ± 3.30.5 ± 2.5-1.0 ± 2.8-1.0 ± 2.2
Change from BL at FU0.3 ± 1.03.3 ± 5.82.8 ± 6.24.8 ± 7.60.3 ± 4.90.5 ± 7.61.3 ± 3.61.0 ± 3.73.5 ± 6.40.0 ± 1.4
PrimaryChange From Baseline in Chemistry Laboratory Test Results by Timepoint: Total Protein. SAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Reported as:
Mean · g/L
Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Total Protein. SAD Group
g/LGroup I PlaceboGroup II PlaceboSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I Placebo + FoodGroup I 100mg + Food
Baseline (pre-dose Day 1)67.5 ± 4.965.5 ± 5.267.0 ± 4.167.3 ± 2.265.3 ± 5.066.0 ± 1.866.3 ± 3.566.0 ± 1.466.5 ± 2.166.3 ± 5.4
Change from BL at 24h1.3 ± 2.73.7 ± 3.61.5 ± 1.03.0 ± 2.42.8 ± 4.06.0 ± 1.63.0 ± 5.09.3 ± 4.82.5 ± 4.92.3 ± 4.6
Change from BL at FU1.5 ± 2.93.3 ± 3.14.0 ± 2.21.8 ± 3.93.3 ± 1.70.8 ± 1.70.0 ± 2.24.8 ± 3.31.0 ± 1.42.3 ± 3.2
PrimaryChange From Baseline in Chemistry Laboratory Test Results by Timepoint: Gamma-GT. SAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value

Time frame:
Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Reported as:
Mean · U/L
Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Gamma-GT. SAD Group
U/LGroup I PlaceboGroup II PlaceboSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I Placebo + FoodGroup I 100mg + Food
Baseline (pre-dose Day 1)23.5 ± 26.719.0 ± 14.124.0 ± 20.023.0 ± 16.212.0 ± 6.817.3 ± 12.130.0 ± 30.821.3 ± 17.229.0 ± 14.113.5 ± 5.1
Change from BL at 24h-0.8 ± 1.71.2 ± 2.10.0 ± 0.80.8 ± 1.70.3 ± 1.31.3 ± 0.5-0.5 ± 4.43.8 ± 3.10.0 ± 2.80.8 ± 1.0
Change from BL at FU-4.0 ± 13.810.0 ± 16.1-1.3 ± 4.513.8 ± 18.42.5 ± 2.411.3 ± 20.5-7.3 ± 15.61.8 ± 2.53.5 ± 3.51.0 ± 0.8
PrimaryChange From Baseline in Chemistry Laboratory Test Results by Timepoint: Alkaline Phosphatase. SAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Reported as:
Mean · U/L
Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Alkaline Phosphatase. SAD Group
U/LGroup I PlaceboGroup II PlaceboSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I Placebo + FoodGroup I 100mg + Food
Baseline (pre-dose Day 1)62.0 ± 18.664.0 ± 19.866.0 ± 18.575.0 ± 32.266.0 ± 25.068.3 ± 28.053.3 ± 10.249.0 ± 8.954.5 ± 2.162.3 ± 21.7
Change from BL at 24h-0.2 ± 3.01.7 ± 3.51.0 ± 2.8-1.8 ± 8.11.0 ± 4.73.8 ± 4.61.3 ± 3.66.8 ± 3.52.0 ± 2.80.8 ± 3.6
Change from BL at FU-1.5 ± 9.01.7 ± 6.31.8 ± 3.5-3.8 ± 18.21.5 ± 3.4-1.5 ± 11.3-2.0 ± 5.44.3 ± 1.52.0 ± 2.8-0.8 ± 4.9
PrimaryChange From Baseline in Chemistry Laboratory Test Results by Timepoint: Creatinine. SAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Reported as:
Mean · mg/dL
Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Creatinine. SAD Group
mg/dLGroup I PlaceboGroup II PlaceboSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I Placebo + FoodGroup I 100mg + Food
Baseline (pre-dose Day 1)0.927 ± 0.0580.768 ± 0.1080.903 ± 0.0280.810 ± 0.0910.838 ± 0.0350.735 ± 0.1080.918 ± 0.0430.838 ± 0.2130.935 ± 0.0780.863 ± 0.024
Change from BL at 24h0.023 ± 0.0500.067 ± 0.0330.080 ± 0.0540.053 ± 0.0760.040 ± 0.0410.115 ± 0.0250.090 ± 0.0430.075 ± 0.1120.015 ± 0.1060.038 ± 0.071
Change from BL at FU-0.003 ± 0.0480.065 ± 0.0480.012 ± 0.0390.073 ± 0.0560.088 ± 0.0680.063 ± 0.028-0.020 ± 0.096-0.017 ± 0.085-0.080 ± 0.0710.063 ± 0.068
PrimaryChange From Baseline in Chemistry Laboratory Test Results by Timepoint: Chloride. SAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Reported as:
Mean · mmol/L
Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Chloride. SAD Group
mmol/LGroup I PlaceboGroup II PlaceboSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I Placebo + FoodGroup I 100mg + Food
Baseline (pre-dose Day 1)102.7 ± 2.7104.0 ± 1.7103.8 ± 1.7104.0 ± 0.8102.3 ± 2.4103.0 ± 1.4103.3 ± 1.5103.8 ± 1.7100.5 ± 2.1101.5 ± 2.1
Change from BL at 24h-0.5 ± 1.4-2.5 ± 1.4-1.5 ± 2.5-3.5 ± 0.60.0 ± 1.8-2.8 ± 1.0-1.3 ± 1.0-3.5 ± 1.72.0 ± 0.0-0.5 ± 1.3
Change from BL at FU-1.5 ± 3.5-3.2 ± 2.2-2.5 ± 2.1-3.5 ± 1.3-0.8 ± 2.2-2.3 ± 2.2-0.8 ± 3.5-3.0 ± 0.03.5 ± 3.50.0 ± 2.7
PrimaryChange From Baseline in Chemistry Laboratory Test Results by Timepoint: Total Bilirubin. SAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Reported as:
Mean · mg/dL
Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Total Bilirubin. SAD Group
mg/dLGroup I PlaceboGroup II PlaceboSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I Placebo + FoodGroup I 100mg + Food
Baseline (pre-dose Day 1)0.82 ± 0.320.75 ± 0.601.03 ± 0.830.68 ± 0.331.18 ± 1.030.53 ± 0.130.63 ± 0.220.31 ± 0.190.45 ± 0.211.10 ± 1.33
Change from BL at 24h0.30 ± 0.260.12 ± 0.080.40 ± 0.080.38 ± 0.13-0.00 ± 0.180.28 ± 0.10-0.03 ± 0.150.31 ± 0.090.15 ± 0.070.27 ± 0.17
Change from BL at FU0.13 ± 0.42-0.02 ± 0.400.05 ± 0.130.13 ± 0.13-0.18 ± 0.330.20 ± 0.180.00 ± 0.290.21 ± 0.100.10 ± 0.14-0.10 ± 0.56
PrimaryChange From Baseline in Chemistry Laboratory Test Results by Timepoint: Alanine Aminotransferase. SAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Reported as:
Mean · U/L
Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Alanine Aminotransferase. SAD Group
U/LGroup I PlaceboGroup II PlaceboSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I Placebo + FoodGroup I 100mg + Food
Baseline (pre-dose Day 1)20.2 ± 11.317.2 ± 6.919.3 ± 3.220.0 ± 10.115.0 ± 6.919.3 ± 6.622.8 ± 12.817.8 ± 6.819.0 ± 1.415.0 ± 5.7
Change from BL at 24h-1.2 ± 2.2-0.3 ± 3.20.8 ± 2.9-1.3 ± 3.51.3 ± 1.3-0.3 ± 2.8-2.0 ± 3.60.3 ± 3.91.5 ± 2.11.5 ± 1.0
Change from BL at FU-1.0 ± 4.55.7 ± 17.72.3 ± 7.88.3 ± 18.01.8 ± 2.66.0 ± 21.5-2.3 ± 5.7-1.0 ± 2.97.5 ± 9.21.8 ± 2.1
PrimaryChange From Baseline in Chemistry Laboratory Test Results by Timepoint: Creatinine Kinase. SAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Reported as:
Mean · U/L
Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Creatinine Kinase. SAD Group
U/LGroup I PlaceboGroup II PlaceboSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I Placebo + FoodGroup I 100mg + Food
Baseline (pre-dose Day 1)118.2 ± 39.378.7 ± 5.9181.8 ± 59.378.8 ± 13.4209.3 ± 223.682.3 ± 28.068.5 ± 49.589.5 ± 45.482.5 ± 89.881.3 ± 29.4
Change from BL at 24h-34.3 ± 23.1-14.0 ± 3.3-51.0 ± 34.6-12.8 ± 1.9-97.8 ± 137.1-15.5 ± 14.1-14.0 ± 23.6-14.8 ± 26.9-31.5 ± 43.1-14.8 ± 8.3
Change from BL at FU13.0 ± 43.716.7 ± 35.7-17.3 ± 88.624.5 ± 39.4-110.0 ± 173.16.0 ± 7.515.8 ± 16.97.0 ± 61.921.5 ± 17.718.0 ± 31.2
PrimaryChange From Baseline in Chemistry Laboratory Test Results by Timepoint: Urea. SAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Reported as:
Mean · mg/dL
Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Urea. SAD Group
mg/dLGroup I PlaceboGroup II PlaceboSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I Placebo + FoodGroup I 100mg + Food
Baseline (pre-dose Day 1)27.5 ± 9.324.7 ± 4.530.0 ± 8.426.0 ± 7.324.0 ± 2.425.3 ± 4.129.3 ± 10.634.8 ± 7.738.5 ± 6.425.8 ± 5.7
Change from BL at 24h0.0 ± 3.90.2 ± 4.4-2.5 ± 5.0-0.3 ± 2.50.0 ± 2.8-0.5 ± 5.2-1.0 ± 4.7-4.0 ± 8.6-9.0 ± 1.4-0.5 ± 3.3
Change from BL at FU1.2 ± 7.10.5 ± 7.7-0.8 ± 3.92.3 ± 7.70.3 ± 4.5-2.3 ± 7.3-0.3 ± 5.4-6.8 ± 11.8-8.0 ± 4.2-1.5 ± 4.7
PrimaryChange From Baseline in Chemistry Laboratory Test Results by Timepoint: Sodium. SAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Reported as:
Mean · mmol/L
Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Sodium. SAD Group
mmol/LGroup I PlaceboGroup II PlaceboSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I Placebo + FoodGroup I 100mg + Food
Baseline (pre-dose Day 1)141.8 ± 1.0142.5 ± 1.2141.5 ± 0.6142.8 ± 1.0141.5 ± 1.7142.0 ± 0.8142.3 ± 1.3143.3 ± 1.0139.5 ± 0.7140.5 ± 1.0
Change from BL at 24h-0.2 ± 1.6-0.7 ± 0.8-0.3 ± 2.2-2.0 ± 1.4-0.8 ± 2.2-1.0 ± 0.80.5 ± 0.6-1.3 ± 1.02.5 ± 2.11.0 ± 2.6
Change from BL at FU-0.3 ± 2.4-1.8 ± 2.00.0 ± 2.7-2.3 ± 2.20.8 ± 1.3-2.0 ± 0.80.5 ± 2.4-2.8 ± 1.34.5 ± 0.71.8 ± 0.5
PrimaryChange From Baseline in Chemistry Laboratory Test Results by Timepoint: Potassium. SAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Reported as:
Mean · mmol/L
Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Potassium. SAD Group
mmol/LGroup I PlaceboGroup II PlaceboSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I Placebo + FoodGroup I 100mg + Food
Baseline (pre-dose Day 1)4.25 ± 0.184.27 ± 0.184.25 ± 0.134.18 ± 0.254.03 ± 0.194.33 ± 0.134.28 ± 0.324.50 ± 0.184.00 ± 0.004.20 ± 0.22
Change from BL at 24h0.17 ± 0.180.17 ± 0.210.07 ± 0.310.23 ± 0.330.30 ± 0.22-0.05 ± 0.260.12 ± 0.10-0.10 ± 0.160.25 ± 0.070.15 ± 0.34
Change from BL at FU0.25 ± 0.100.10 ± 0.260.30 ± 0.220.20 ± 0.290.50 ± 0.220.10 ± 0.270.08 ± 0.36-0.05 ± 0.100.30 ± 0.140.33 ± 0.17
PrimaryChange From Baseline in Chemistry Laboratory Test Results by Timepoint: Phosphate. SAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Reported as:
Mean · mmol/L
Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Phosphate. SAD Group
mmol/LGroup I PlaceboGroup II PlaceboSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I Placebo + FoodGroup I 100mg + Food
Baseline (pre-dose Day 1)1.042 ± 0.0660.998 ± 0.1221.120 ± 0.1171.085 ± 0.1331.023 ± 0.0810.983 ± 0.1651.088 ± 0.1421.128 ± 0.1931.410 ± 0.5521.105 ± 0.154
Change from BL at 24h0.033 ± 0.126-0.045 ± 0.094-0.035 ± 0.169-0.133 ± 0.1050.045 ± 0.172-0.060 ± 0.1110.032 ± 0.116-0.090 ± 0.164-0.180 ± 0.999-0.015 ± 0.079
Change from BL at FU-0.020 ± 0.1160.030 ± 0.172-0.077 ± 0.126-0.018 ± 0.1820.003 ± 0.046-0.070 ± 0.153-0.090 ± 0.121-0.105 ± 0.135-0.395 ± 0.205-0.080 ± 0.097
PrimaryChange From Baseline in Chemistry Laboratory Test Results by Timepoint: Calcium (Corrected for Albumin). SAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Reported as:
Mean · mmol/L
Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Calcium (Corrected for Albumin). SAD Group
mmol/LGroup I PlaceboGroup II PlaceboSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I Placebo + FoodGroup I 100mg + Food
Baseline (pre-dose Day 1)2.380 ± 0.0732.303 ± 0.0872.290 ± 0.1142.288 ± 0.0302.373 ± 0.1162.358 ± 0.0692.353 ± 0.1022.323 ± 0.0442.340 ± 0.0002.360 ± 0.118
Change from BL at 24h0.033 ± 0.0450.095 ± 0.0660.098 ± 0.0500.093 ± 0.0280.058 ± 0.1050.085 ± 0.0590.078 ± 0.0750.148 ± 0.055-0.005 ± 0.0210.075 ± 0.088
Change from BL at FU0.010 ± 0.0410.062 ± 0.0750.085 ± 0.0700.073 ± 0.0980.042 ± 0.030-0.032 ± 0.006-0.005 ± 0.0330.090 ± 0.059-0.065 ± 0.0490.055 ± 0.039
PrimaryChange From Baseline in Chemistry Laboratory Test Results by Timepoint: Uric Acid. SAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Reported as:
Mean · mg/dL
Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Uric Acid. SAD Group
mg/dLGroup I PlaceboGroup II PlaceboSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I Placebo + FoodGroup I 100mg + Food
Baseline (pre-dose Day 1)5.52 ± 0.844.85 ± 0.845.75 ± 0.424.80 ± 0.375.48 ± 0.824.75 ± 0.795.48 ± 1.075.10 ± 0.965.45 ± 0.215.50 ± 1.41
Change from BL at 24h-0.25 ± 0.40-0.13 ± 0.23-0.28 ± 0.25-0.20 ± 0.24-0.30 ± 0.12-0.25 ± 0.24-0.20 ± 0.320.15 ± 0.42-0.60 ± 0.28-0.28 ± 0.40
Change from BL at FU0.28 ± 0.260.32 ± 0.500.22 ± 0.790.40 ± 0.430.35 ± 0.530.30 ± 0.080.18 ± 0.680.23 ± 0.220.40 ± 0.280.33 ± 0.51
PrimaryChange From Baseline in Chemistry Laboratory Test Results by Timepoint: Triiodothyronine (T3). SAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Reported as:
Mean · pg/mL
Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Triiodothyronine (T3). SAD Group
pg/mLGroup I PlaceboGroup II PlaceboSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I Placebo + FoodGroup I 100mg + Food
Baseline (pre-dose Day 1)3.65 ± 0.353.23 ± 0.123.73 ± 0.213.40 ± 0.223.48 ± 0.303.18 ± 0.173.18 ± 0.173.33 ± 0.193.60 ± 0.143.63 ± 0.41
Change from BL at 24h-0.35 ± 0.28-0.10 ± 0.24-0.22 ± 0.170.05 ± 0.31-0.07 ± 0.10-0.23 ± 0.10-0.23 ± 0.36-0.13 ± 0.15-0.40 ± 0.00-0.25 ± 0.17
Change from BL at FU-0.30 ± 0.280.42 ± 0.23-0.23 ± 0.130.30 ± 0.23-0.13 ± 0.170.50 ± 0.340.05 ± 0.130.20 ± 0.08-0.30 ± 0.14-0.28 ± 0.15
PrimaryChange From Baseline in Chemistry Laboratory Test Results by Timepoint: Lipase. SAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Reported as:
Mean · U/L
Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Lipase. SAD Group
U/LGroup I PlaceboGroup II PlaceboSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I Placebo + FoodGroup I 100mg + Food
Baseline (pre-dose Day 1)31.0 ± 8.234.8 ± 16.239.0 ± 9.829.3 ± 12.727.3 ± 7.533.0 ± 9.230.0 ± 8.025.5 ± 6.242.0 ± 14.131.1 ± 11.8
Change from BL at 24h-1.5 ± 3.1-7.5 ± 18.5-6.3 ± 6.8-1.8 ± 2.91.3 ± 0.57.3 ± 16.5-1.3 ± 3.4-4.8 ± 5.1-0.5 ± 2.1-2.5 ± 5.1
Change from BL at FU-1.0 ± 2.3-1.0 ± 5.5-4.5 ± 12.48.0 ± 27.21.5 ± 3.0-5.0 ± 3.7-2.0 ± 6.59.3 ± 19.8-7.0 ± 4.2-2.5 ± 3.0
PrimaryChange From Baseline in Chemistry Laboratory Test Results by Timepoint: (Fasting) Glucose. SAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Reported as:
Mean · mg/dL
Change From Baseline in Chemistry Laboratory Test Results by Timepoint: (Fasting) Glucose. SAD Group
mg/dLGroup I PlaceboGroup II PlaceboSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I Placebo + FoodGroup I 100mg + Food
Baseline (pre-dose Day 1)85.0 ± 7.386.8 ± 8.984.8 ± 7.488.5 ± 12.277.8 ± 5.786.3 ± 9.487.0 ± 4.295.5 ± 18.784.0 ± 5.778.8 ± 3.8
Change from BL at 24h-1.0 ± 3.21.2 ± 5.22.0 ± 3.7-2.0 ± 3.27.0 ± 4.5-1.0 ± 1.40.5 ± 3.1-2.3 ± 1.04.0 ± 1.43.3 ± 1.9
Change from BL at FU-0.2 ± 7.05.5 ± 6.9-0.3 ± 7.76.3 ± 6.77.3 ± 6.20.5 ± 5.9-1.3 ± 5.4-1.5 ± 1.72.0 ± 8.56.3 ± 3.8
PrimaryChange From Baseline in Chemistry Laboratory Test Results by Timepoint: Human Serum Albumin. SAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Reported as:
Mean · g/L
Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Human Serum Albumin. SAD Group
g/LGroup I PlaceboGroup II PlaceboSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I Placebo + FoodGroup I 100mg + Food
Baseline (pre-dose Day 1)46.2 ± 3.145.0 ± 2.845.3 ± 3.945.0 ± 1.245.3 ± 3.446.0 ± 1.444.0 ± 1.244.3 ± 1.544.0 ± 1.445.8 ± 3.1
Change from BL at 24h-0.3 ± 1.21.7 ± 1.50.3 ± 1.52.0 ± 2.61.5 ± 3.73.5 ± 1.31.5 ± 3.15.3 ± 2.60.5 ± 2.10.0 ± 2.7
Change from BL at FU0.2 ± 1.82.0 ± 1.42.3 ± 1.52.0 ± 2.81.0 ± 1.20.5 ± 1.30.0 ± 0.83.5 ± 2.10.0 ± 0.005 ± 1.7
PrimaryChange From Baseline in Chemistry Laboratory Test Results by Timepoint: Cholesterol. SAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Reported as:
Mean · mg/dL
Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Cholesterol. SAD Group
mg/dLGroup I PlaceboGroup II PlaceboSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I Placebo + FoodGroup I 100mg + Food
Baseline (pre-dose Day 1)176.0 ± 47.7151.0 ± 26.6146.3 ± 37.5149.0 ± 38.3146.5 ± 49.7167.5 ± 42.3212.8 ± 48.2174.5 ± 34.5200.5 ± 10.6166.5 ± 28.1
Change from BL at 24h4.8 ± 5.512.5 ± 10.65.3 ± 2.25.3 ± 6.49.5 ± 14.019.5 ± 4.08.3 ± 21.025.0 ± 12.712.5 ± 12.05.8 ± 10.7
Change from BL at FU5.0 ± 20.426.3 ± 27.225.3 ± 5.121.5 ± 15.528.3 ± 17.724.3 ± 16.7-13.8 ± 33.76.8 ± 5.4-2.5 ± 41.78.3 ± 9.3
PrimaryChange From Baseline in Chemistry Laboratory Test Results by Timepoint: High Density Lipoproteins. SAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Reported as:
Mean · mg/dL
Change From Baseline in Chemistry Laboratory Test Results by Timepoint: High Density Lipoproteins. SAD Group
mg/dLGroup I PlaceboGroup II PlaceboSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I Placebo + FoodGroup I 100mg + Food
Baseline (pre-dose Day 1)50.0 ± 11.149.8 ± 8.445.5 ± 11.049.5 ± 8.940.0 ± 4.154.5 ± 5.551.5 ± 9.648.0 ± 13.347.0 ± 17.045.8 ± 7.3
Change from BL at 24h-2.8 ± 2.40.5 ± 3.11.0 ± 1.2-2.5 ± 2.9-1.3 ± 2.12.8 ± 2.2-3.0 ± 6.010.0 ± 7.32.5 ± 7.8-0.3 ± 1.5
Change from BL at FU1.8 ± 5.24.5 ± 5.06.3 ± 4.63.0 ± 3.67.3 ± 2.62.8 ± 5.1-3.0 ± 9.98.8 ± 7.4-2.0 ± 7.11.5 ± 6.1
PrimaryChange From Baseline in Chemistry Laboratory Test Results by Timepoint: Triglycerides. SAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Reported as:
Mean · mg/dL
Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Triglycerides. SAD Group
mg/dLGroup I PlaceboGroup II PlaceboSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I Placebo + FoodGroup I 100mg + Food
Baseline (pre-dose Day 1)72.8 ± 19.088.5 ± 62.157.3 ± 13.084.5 ± 46.872.0 ± 9.671.0 ± 33.676.3 ± 15.7117.0 ± 99.592.5 ± 57.386.3 ± 20.8
Change from BL at 24h16.7 ± 7.219.0 ± 17.310.3 ± 3.031.0 ± 18.120.3 ± 16.322.5 ± 18.427.0 ± 9.5-10.3 ± 46.71.5 ± 29.07.8 ± 20.2
Change from BL at FU16.5 ± 24.524.5 ± 58.630.8 ± 48.847.3 ± 75.312.5 ± 19.337.5 ± 86.537.8 ± 47.1-16.5 ± 48.643.5 ± 89.8-1.8 ± 18.6
PrimaryChange From Baseline in Chemistry Laboratory Test Results by Timepoint: Low Density Lipoproteins. SAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Reported as:
Mean · mg/dL
Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Low Density Lipoproteins. SAD Group
mg/dLGroup I PlaceboGroup II PlaceboSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I Placebo + FoodGroup I 100mg + Food
Baseline (pre-dose Day 1)111.1 ± 41.983.5 ± 24.988.9 ± 32.582.5 ± 35.392.3 ± 46.498.7 ± 35.6145.9 ± 45.7103.1 ± 40.0134.5 ± 16.3103.5 ± 25.7
Change from BL at 24h4.5 ± 6.98.3 ± 4.62.9 ± 3.11.4 ± 6.46.4 ± 10.312.8 ± 2.65.7 ± 16.216.7 ± 7.810.0 ± 9.94.4 ± 7.1
Change from BL at FU0.3 ± 19.717.0 ± 15.613.3 ± 10.89.6 ± 6.918.5 ± 16.414.2 ± 6.2-17.9 ± 35.81.3 ± 7.7-8.5 ± 30.47.2 ± 6.8
PrimaryChange From Baseline in Chemistry Laboratory Test Results by Timepoint: Bicarbonate. SAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Reported as:
Mean · mmol/L
Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Bicarbonate. SAD Group
mmol/LGroup I PlaceboGroup II PlaceboSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I Placebo + FoodGroup I 100mg + Food
Baseline (pre-dose Day 1)25.68 ± 1.3825.22 ± 0.5124.78 ± 1.0925.85 ± 0.5324.85 ± 1.2124.28 ± 0.3327.05 ± 0.9126.03 ± 1.8024.90 ± 0.7125.93 ± 0.84
Change from BL at 24h-0.05 ± 1.150.28 ± 1.311.05 ± 1.271.18 ± 0.900.40 ± 0.942.35 ± 0.70-0.17 ± 0.940.05 ± 1.551.95 ± 0.640.05 ± 0.39
Change from BL at FU-1.22 ± 1.380.97 ± 1.04-0.58 ± 1.460.95 ± 0.88-0.15 ± 0.551.65 ± 1.20-2.38 ± 1.64-0.20 ± 1.03-0.55 ± 0.49-1.23 ± 0.30
PrimaryChange From Baseline in Chemistry Laboratory Test Results by Timepoint: Thyroid-stimulating Hormone. SAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Reported as:
Mean · mU/L
Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Thyroid-stimulating Hormone. SAD Group
mU/LGroup I PlaceboGroup II PlaceboSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I Placebo + FoodGroup I 100mg + Food
Baseline (pre-dose Day 1)1.45 ± 0.561.26 ± 0.641.14 ± 0.361.14 ± 0.551.50 ± 0.971.55 ± 0.661.83 ± 0.781.59 ± 1.032.57 ± 2.311.93 ± 0.95
Change from BL at 24h-0.20 ± 0.090.04 ± 0.29-0.12 ± 0.22-0.03 ± 0.180.07 ± 0.220.46 ± 0.520.05 ± 0.35-0.12 ± 0.25-0.54 ± 0.65-0.42 ± 0.42
Change from BL at FU0.08 ± 0.350.45 ± 1.020.10 ± 0.220.77 ± 0.920.32 ± 0.270.11 ± 0.580.17 ± 0.42-0.06 ± 0.21-0.69 ± 0.73-0.10 ± 0.22
PrimaryChange From Baseline in Chemistry Laboratory Test Results by Timepoint: Thyroxine (T4). SAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Reported as:
Mean · ng/dL
Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Thyroxine (T4). SAD Group
ng/dLGroup I PlaceboGroup II PlaceboSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I Placebo + FoodGroup I 100mg + Food
Baseline (pre-dose Day 1)1.27 ± 0.141.22 ± 0.161.30 ± 0.141.38 ± 0.171.25 ± 0.101.08 ± 0.051.20 ± 0.141.15 ± 0.061.35 ± 0.071.22 ± 0.17
Change from BL at 24h-0.05 ± 0.080.03 ± 0.05-0.08 ± 0.10-0.08 ± 0.10-0.05 ± 0.060.12 ± 0.050.05 ± 0.130.10 ± 0.080.05 ± 0.070.03 ± 0.13
Change from BL at FU0.03 ± 0.100.15 ± 0.100.02 ± 0.220.05 ± 0.060.07 ± 0.050.22 ± 0.050.05 ± 0.100.13 ± 0.05-0.10 ± 0.140.10 ± 0.08
PrimaryChange From Baseline in Chemistry Laboratory Test Results by Timepoint: Lactate. SAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of clinical chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline (pre-dose Day 1), 24h post dose, FU (7 days post dose)
Reported as:
Mean · mg/dL
Change From Baseline in Chemistry Laboratory Test Results by Timepoint: Lactate. SAD Group
mg/dLGroup I PlaceboGroup II PlaceboSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I Placebo + FoodGroup I 100mg + Food
Baseline (pre-dose Day 1)7.98 ± 2.477.28 ± 1.868.65 ± 3.208.23 ± 2.048.10 ± 2.939.03 ± 2.087.53 ± 0.978.58 ± 2.689.85 ± 1.348.33 ± 1.50
Change from BL at 24h-0.80 ± 1.831.40 ± 2.82-2.08 ± 2.412.10 ± 3.81-0.50 ± 1.670.88 ± 3.620.78 ± 1.753.25 ± 1.54-1.05 ± 0.070.40 ± 2.22
Change from BL at FU1.05 ± 4.593.80 ± 3.122.25 ± 5.843.45 ± 3.451.93 ± 6.230.70 ± 2.45-0.02 ± 3.404.33 ± 3.08-0.15 ± 0.641.70 ± 4.59
PrimaryChange From Baseline in Chemistry Laboratory Test Results by Time Point: Total Protein. MAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of hematology parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline (pre-dose Day1), Day 3, Day 8, FU (one week after last dosing)
Reported as:
Mean · g/L
Change From Baseline in Chemistry Laboratory Test Results by Time Point: Total Protein. MAD Group
g/LMAD Group IIIMAD Group IVMAD Group VPlacebo
Baseline (pre-dose Day 1)65.3 ± 3.867.3 ± 4.663.8 ± 1.366.0 ± 2.1
Change from BL at Day 34.0 ± 2.42.3 ± 1.72.5 ± 1.71.7 ± 2.3
Change from BL at Day 87.0 ± 2.94.3 ± 4.36.0 ± 4.14.8 ± 1.7
Change from BL at FU5.0 ± 3.44.8 ± 4.14.0 ± 2.91.8 ± 2.0
PrimaryChange From Baseline in Chemistry Laboratory Test Results by Time Point: Alkaline Phosphatase. MAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline, Day 3, Day 8, FU (one week after last dosing)
Reported as:
Mean · U/L
Change From Baseline in Chemistry Laboratory Test Results by Time Point: Alkaline Phosphatase. MAD Group
U/LMAD Group IIIMAD Group IVMAD Group VPlacebo
Baseline (pre-dose Day 1)66.0 ± 16.167.3 ± 10.755.3 ± 7.352.3 ± 9.5
Change from BL at Day 37.3 ± 6.72.0 ± 1.41.5 ± 3.91.8 ± 1.8
Change from BL at Day 813.0 ± 9.75.0 ± 4.26.0 ± 6.43.3 ± 1.9
Change from BL at FU9.0 ± 13.310.8 ± 4.69.8 ± 5.23.3 ± 4.0
PrimaryChange From Baseline in Chemistry Laboratory Test Results by Time Point: Aspartate Aminotransferase. MAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline, Day 3, Day 8, FU (one week after last dosing)
Reported as:
Mean · U/L
Change From Baseline in Chemistry Laboratory Test Results by Time Point: Aspartate Aminotransferase. MAD Group
U/LMAD Group IIIMAD Group IVMAD Group VPlacebo
Baseline (pre-dose Day 1)20.3 ± 3.821.5 ± 5.718.5 ± 0.623.0 ± 6.6
Change from BL at Day 3-2.0 ± 4.2-5.0 ± 1.4-2.5 ± 1.3-1.7 ± 3.6
Change from BL at Day 8-1.0 ± 6.1-2.8 ± 1.9-0.3 ± 2.8-1.5 ± 4.8
Change from BL at FU1.5 ± 3.91.3 ± 4.69.8 ± 16.32.8 ± 8.2
PrimaryChange From Baseline in Chemistry Laboratory Test Results by Time Point: Creatine Kinase. MAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline, Day 3, Day 8, FU (one week after last dosing)
Reported as:
Mean · U/L
Change From Baseline in Chemistry Laboratory Test Results by Time Point: Creatine Kinase. MAD Group
U/LMAD Group IIIMAD Group IVMAD Group VPlacebo
Baseline (pre-dose Day 1)129.5 ± 62.0192.3 ± 149.4146.5 ± 70.8229.8 ± 156.0
Change from BL at Day 3-48.5 ± 40.7-68.8 ± 57.3-58.0 ± 53.3-106.5 ± 115.2
Change from BL at Day 8-50.8 ± 49.4-83.8 ± 91.7-68.0 ± 57.7-123.5 ± 144.9
Change from BL at FU27.0 ± 23.1-7.5 ± 81.2150.5 ± 313.342.2 ± 153.5
PrimaryChange From Baseline in Chemistry Laboratory Test Results by Time Point: Gamma GT. MAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline, Day 3, Day 8, FU (one week after last dosing)
Reported as:
Mean · U/L
Change From Baseline in Chemistry Laboratory Test Results by Time Point: Gamma GT. MAD Group
U/LMAD Group IIIMAD Group IVMAD Group VPlacebo
Baseline (pre-dose Day 1)15.5 ± 7.018.3 ± 9.220.5 ± 14.521.5 ± 11.3
Change from BL at Day 30.5 ± 1.00.3 ± 1.32.0 ± 2.20.7 ± 1.2
Change from BL at Day 80.8 ± 1.90.3 ± 3.01.8 ± 2.80.0 ± 2.2
Change from BL at FU1.3 ± 1.3-0.5 ± 3.11.8 ± 2.2-0.8 ± 2.5
PrimaryChange From Baseline in Chemistry Laboratory Test Results by Time Point: Total Bilirubin. MAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline, Day 3, Day 8, FU (one week after last dosing)
Reported as:
Mean · mg/dL
Change From Baseline in Chemistry Laboratory Test Results by Time Point: Total Bilirubin. MAD Group
mg/dLMAD Group IIIMAD Group IVMAD Group VPlacebo
Baseline (pre-dose Day 1)0.50 ± 0.470.55 ± 0.130.63 ± 0.150.65 ± 0.29
Change from BL at Day 30.38 ± 0.220.05 ± 0.130.20 ± 0.160.13 ± 0.08
Change from BL at Day 80.33 ± 0.260.03 ± 0.210.18 ± 0.250.08 ± 0.08
Change from BL at FU-0.02 ± 0.32-0.08 ± 0.210.08 ± 0.22-0.05 ± 0.19
PrimaryChange From Baseline in Chemistry Laboratory Test Results by Time Point: Urea. MAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline, Day 3, Day 8, FU (one week after last dosing)
Reported as:
Mean · mg/dL
Change From Baseline in Chemistry Laboratory Test Results by Time Point: Urea. MAD Group
mg/dLMAD Group IIIMAD Group IVMAD Group VPlacebo
Baseline (pre-dose Day 1)24.8 ± 3.928.0 ± 5.529.8 ± 5.130.2 ± 3.5
Change from BL at Day 36.0 ± 2.22.8 ± 2.42.0 ± 2.62.5 ± 3.0
Change from BL at Day 85.8 ± 6.9-0.5 ± 3.10.5 ± 1.3-1.0 ± 4.5
Change from BL at FU2.3 ± 8.4-0.5 ± 6.8-0.5 ± 7.1-0.3 ± 6.7
PrimaryChange From Baseline in Chemistry Laboratory Test Results by Time Point: Creatinine. MAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline, Day 3, Day 8, FU (one week after last dosing)
Reported as:
Mean · mg/dL
Change From Baseline in Chemistry Laboratory Test Results by Time Point: Creatinine. MAD Group
mg/dLMAD Group IIIMAD Group IVMAD Group VPlacebo
Baseline (pre-dose Day 1)0.910 ± 0.0420.960 ± 0.0790.913 ± 0.0670.897 ± 0.110
Change from BL at Day 30.095 ± 0.0250.122 ± 0.0330.165 ± 0.0310.057 ± 0.050
Change from BL at Day 80.005 ± 0.2470.122 ± 0.0690.133 ± 0.0820.053 ± 0.056
Change from BL at FU0.008 ± 0.130-0.020 ± 0.0240.017 ± 0.0430.007 ± 0.039
PrimaryChange From Baseline in Chemistry Laboratory Test Results by Time Point: Sodium. MAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline, Day 3, Day 8, FU (one week after last dosing)
Reported as:
Mean · mmol/L
Change From Baseline in Chemistry Laboratory Test Results by Time Point: Sodium. MAD Group
mmol/LMAD Group IIIMAD Group IVMAD Group VPlacebo
Baseline (pre-dose Day 1)143.8 ± 1.0141.3 ± 0.5141.0 ± 1.4142.0 ± 0.9
Change from BL at Day 3-0.5 ± 0.6-1.5 ± 0.60.8 ± 0.5-1.0 ± 0.6
Change from BL at Day 8-3.0 ± 0.80.8 ± 0.51.0 ± 0.8-0.5 ± 1.4
Change from BL at FU-1.5 ± 1.0-0.3 ± 2.22.0 ± 2.20.2 ± 2.1
PrimaryChange From Baseline in Chemistry Laboratory Test Results by Time Point: Potassium. MAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline, Day 3, Day 8, FU (one week after last dosing)
Reported as:
Mean · mmol/L
Change From Baseline in Chemistry Laboratory Test Results by Time Point: Potassium. MAD Group
mmol/LMAD Group IIIMAD Group IVMAD Group VPlacebo
Baseline (pre-dose Day 1)4.20 ± 0.084.35 ± 0.194.40 ± 0.404.32 ± 0.17
Change from BL at Day 30.45 ± 0.190.33 ± 0.370.10 ± 0.290.52 ± 0.49
Change from BL at Day 80.07 ± 0.300.15 ± 0.390.25 ± 0.420.15 ± 0.41
Change from BL at FU0.25 ± 0.390.45 ± 0.310.25 ± 0.590.30 ± 0.26
PrimaryChange From Baseline in Chemistry Laboratory Test Results by Time Point: Chloride. MAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline, Day 3, Day 8, FU (one week after last dosing)
Reported as:
Mean · mmol/L
Change From Baseline in Chemistry Laboratory Test Results by Time Point: Chloride. MAD Group
mmol/LMAD Group IIIMAD Group IVMAD Group VPlacebo
Baseline (pre-dose Day 1)103.8 ± 2.2101.5 ± 0.6102.0 ± 1.8102.2 ± 1.5
Change from BL at Day 3-2.5 ± 0.6-2.0 ± 1.8-1.5 ± 0.6-1.5 ± 0.8
Change from BL at Day 8-3.5 ± 1.0-2.0 ± 1.4-2.8 ± 1.0-2.2 ± 2.1
Change from BL at FU-2.0 ± 0.0-2.3 ± 1.9-2.0 ± 0.8-1.3 ± 1.5
PrimaryChange From Baseline in Chemistry Laboratory Test Results by Time Point: Calcium (Corrected for Albumin). MAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline, Day 3, Day 8, FU (one week after last dosing)
Reported as:
Mean · mmol/L
Change From Baseline in Chemistry Laboratory Test Results by Time Point: Calcium (Corrected for Albumin). MAD Group
mmol/LMAD Group IIIMAD Group IVMAD Group VPlacebo
Baseline (pre-dose Day 1)2.278 ± 0.1172.310 ± 0.0582.265 ± 0.0242.323 ± 0.039
Change from BL at Day 30.105 ± 0.0510.083 ± 0.0670.048 ± 0.0680.068 ± 0.046
Change from BL at Day 80.127 ± 0.0910.083 ± 0.0630.100 ± 0.0950.088 ± 0.037
Change from BL at FU0.087 ± 0.0880.083 ± 0.0750.045 ± 0.0820.055 ± 0.037
PrimaryChange From Baseline in Chemistry Laboratory Test Results by Time Point: Uric Acid. MAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline, Day 3, Day 8, FU (one week after last dosing)
Reported as:
Mean · mg/dL
Change From Baseline in Chemistry Laboratory Test Results by Time Point: Uric Acid. MAD Group
mg/dLMAD Group IIIMAD Group IVMAD Group VPlacebo
Baseline (pre-dose Day 1)5.65 ± 1.674.93 ± 0.915.40 ± 0.805.25 ± 1.14
Change from BL at Day 30.50 ± 0.560.58 ± 0.390.75 ± 0.62-0.07 ± 0.31
Change from BL at Day 80.28 ± 1.14-0.02 ± 0.430.15 ± 0.58-0.63 ± 0.52
Change from BL at FU0.08 ± 0.920.55 ± 0.520.22 ± 0.81-0.05 ± 0.42
PrimaryChange From Baseline in Chemistry Laboratory Test Results by Time Point: Lipase. MAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline, Day 3, Day 8, FU (one week after last dosing)
Reported as:
Mean · U/L
Change From Baseline in Chemistry Laboratory Test Results by Time Point: Lipase. MAD Group
U/LMAD Group IIIMAD Group IVMAD Group VPlacebo
Baseline (pre-dose Day 1)26.5 ± 6.126.5 ± 3.332.8 ± 12.134.2 ± 10.3
Change from BL at Day 3-1.8 ± 3.10.0 ± 1.826.0 ± 55.41.2 ± 4.4
Change from BL at Day 8-0.3 ± 4.11.3 ± 7.450.5 ± 106.41.0 ± 5.1
Change from BL at FU3.5 ± 3.317.3 ± 24.4-2.8 ± 7.4-1.8 ± 7.6
PrimaryChange From Baseline in Chemistry Laboratory Test Results by Time Point: Alanine Aminotransferase. MAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline, Day 3, Day 8, FU (one week after last dosing)
Reported as:
Mean · U/L
Change From Baseline in Chemistry Laboratory Test Results by Time Point: Alanine Aminotransferase. MAD Group
U/LMAD Group IIIMAD Group IVMAD Group VPlacebo
Baseline (pre-dose Day 1)25.3 ± 9.721.3 ± 17.420.5 ± 6.822.3 ± 5.2
Change from BL at Day 30.0 ± 5.9-0.3 ± 2.2-1.3 ± 0.52.0 ± 4.2
Change from BL at Day 8-1.8 ± 12.92.3 ± 2.60.3 ± 5.42.8 ± 5.9
Change from BL at FU1.3 ± 11.46.3 ± 8.34.8 ± 7.92.3 ± 6.9
PrimaryChange From Baseline in Chemistry Laboratory Test Results by Time Point: Phosphate. MAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline, Day 3, Day 8, FU (one week after last dosing)
Reported as:
Mean · mmol/L
Change From Baseline in Chemistry Laboratory Test Results by Time Point: Phosphate. MAD Group
mmol/LMAD Group IIIMAD Group IVMAD Group VPlacebo
Baseline (pre-dose Day 1)0.978 ± 0.0941.033 ± 0.1640.920 ± 0.1211.000 ± 0.162
Change from BL at Day 30.102 ± 0.0330.003 ± 0.0740.015 ± 0.073-0.005 ± 0.111
Change from BL at Day 80.052 ± 0.1160.000 ± 0.085-0.020 ± 0.068-0.002 ± 0.113
Change from BL at FU-0.030 ± 0.131-0.010 ± 0.0340.053 ± 0.189-0.002 ± 0.190
PrimaryChange From Baseline in Chemistry Laboratory Test Results by Time Point: Human Serum Albumin. MAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline, Day 3, Day 8, FU (one week after last dosing)
Reported as:
Mean · g/L
Change From Baseline in Chemistry Laboratory Test Results by Time Point: Human Serum Albumin. MAD Group
g/LMAD Group IIIMAD Group IVMAD Group VPlacebo
Baseline (pre-dose Day 1)43.3 ± 2.245.5 ± 3.142.8 ± 0.544.7 ± 1.5
Change from BL at Day 33.3 ± 2.23.8 ± 1.31.3 ± 1.01.5 ± 2.1
Change from BL at Day 85.3 ± 2.63.5 ± 3.04.0 ± 1.83.8 ± 1.8
Change from BL at FU2.8 ± 2.13.0 ± 2.43.3 ± 2.11.7 ± 1.4
PrimaryChange From Baseline in Chemistry Laboratory Test Results by Time Point: Fasting Glucose. MAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline, Day 3, Day 8, FU (one week after last dosing)
Reported as:
Mean · mg/dL
Change From Baseline in Chemistry Laboratory Test Results by Time Point: Fasting Glucose. MAD Group
mg/dLMAD Group IIIMAD Group IVMAD Group VPlacebo
Baseline (pre-dose Day 1)89.0 ± 5.485.5 ± 13.889.8 ± 7.587.2 ± 10.0
Change from BL at Day 3-6.8 ± 4.52.8 ± 6.3-6.8 ± 7.91.5 ± 2.5
Change from BL at Day 8-6.5 ± 7.0-9.5 ± 5.5-7.0 ± 6.1-3.5 ± 7.7
Change from BL at FU-2.2 ± 1.42.0 ± 5.7-10.8 ± 7.80.0 ± 7.2
PrimaryChange From Baseline in Chemistry Laboratory Test Results by Time Point: Cholesterol. MAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline, Day 3, Day 8, FU (one week after last dosing)
Reported as:
Mean · mg/dL
Change From Baseline in Chemistry Laboratory Test Results by Time Point: Cholesterol. MAD Group
mg/dLMAD Group IIIMAD Group IVMAD Group VPlacebo
Baseline (pre-dose Day 1)192.8 ± 33.5191.0 ± 11.3203.5 ± 7.4177.8 ± 30.7
Change from BL at Day 320.0 ± 11.58.8 ± 9.713.5 ± 4.019.7 ± 15.3
Change from BL at Day 832.3 ± 25.32.5 ± 20.513.3 ± 17.724.3 ± 24.4
Change from BL at FU9.3 ± 14.28.0 ± 22.29.8 ± 17.8-5.5 ± 8.6
PrimaryChange From Baseline in Chemistry Laboratory Test Results by Time Point: Triglycerides. MAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline, Day 3, Day 8, FU (one week after last dosing)
Reported as:
Mean · mg/dL
Change From Baseline in Chemistry Laboratory Test Results by Time Point: Triglycerides. MAD Group
mg/dLMAD Group IIIMAD Group IVMAD Group VPlacebo
Baseline (pre-dose Day 1)140.3 ± 77.783.5 ± 26.3114.0 ± 74.690.2 ± 67.5
Change from BL at Day 314.8 ± 32.235.5 ± 32.730.5 ± 30.014.8 ± 29.3
Change from BL at Day 817.8 ± 44.246.8 ± 26.969.0 ± 42.128.3 ± 18.2
Change from BL at FU16.0 ± 52.10.5 ± 33.520.3 ± 56.6-8.0 ± 39.0
PrimaryChange From Baseline in Chemistry Laboratory Test Results by Time Point: Low Density Lipoproteins. MAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline, Day 3, Day 8, FU (one week after last dosing)
Reported as:
Mean · mg/dL
Change From Baseline in Chemistry Laboratory Test Results by Time Point: Low Density Lipoproteins. MAD Group
mg/dLMAD Group IIIMAD Group IVMAD Group VPlacebo
Baseline (pre-dose Day 1)114.1 ± 32.7112.9 ± 19.0127.0 ± 18.193.3 ± 23.7
Change from BL at Day 317.9 ± 14.54.9 ± 5.29.0 ± 7.918.8 ± 13.6
Change from BL at Day 833.2 ± 32.81.4 ± 13.83.5 ± 20.025.6 ± 25.7
Change from BL at FU8.1 ± 11.06.9 ± 9.6-1.5 ± 20.7-1.9 ± 9.7
PrimaryChange From Baseline in Chemistry Laboratory Test Results by Time Point: High Density Lipoproteins. MAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline, Day 3, Day 8, FU (one week after last dosing)
Reported as:
Mean · mg/dL
Change From Baseline in Chemistry Laboratory Test Results by Time Point: High Density Lipoproteins. MAD Group
mg/dLMAD Group IIIMAD Group IVMAD Group VPlacebo
Baseline (pre-dose Day 1)51.0 ± 15.161.0 ± 20.153.5 ± 20.566.8 ± 17.7
Change from BL at Day 3-1.0 ± 5.7-3.0 ± 4.8-1.5 ± 5.8-2.5 ± 6.2
Change from BL at Day 8-5.0 ± 6.1-7.8 ± 8.6-3.5 ± 11.2-7.0 ± 6.6
Change from BL at FU-2.5 ± 2.11.3 ± 9.97.5 ± 12.1-2.2 ± 8.9
PrimaryChange From Baseline in Chemistry Laboratory Test Results by Time Point: Thyroid-stimulating Hormone. MAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline, Day 3, Day 8, FU (one week after last dosing)
Reported as:
Mean · mU/L
Change From Baseline in Chemistry Laboratory Test Results by Time Point: Thyroid-stimulating Hormone. MAD Group
mU/LMAD Group IIIMAD Group IVMAD Group VPlacebo
Baseline (pre-dose Day 1)1.41 ± 0.781.48 ± 0.451.20 ± 0.361.58 ± 0.41
Change from BL at Day 30.11 ± 0.330.09 ± 0.210.48 ± 0.540.25 ± 0.39
Change from BL at Day 80.28 ± 0.350.45 ± 0.230.75 ± 0.520.85 ± 0.54
Change from BL at FU0.16 ± 0.50-0.15 ± 0.290.05 ± 0.480.05 ± 0.39
PrimaryChange From Baseline in Chemistry Laboratory Test Results by Time Point: Trilodothyronine (T3). MAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline, Day 3, Day 8, FU (one week after last dosing)
Reported as:
Mean · pg/mL
Change From Baseline in Chemistry Laboratory Test Results by Time Point: Trilodothyronine (T3). MAD Group
pg/mLMAD Group IIIMAD Group IVMAD Group VPlacebo
Baseline (pre-dose Day 1)3.35 ± 0.583.35 ± 0.263.30 ± 0.143.08 ± 0.35
Change from BL at Day 3-0.05 ± 0.19-0.28 ± 0.29-0.15 ± 0.19-0.15 ± 0.34
Change from BL at Day 8-0.32 ± 0.300.10 ± 0.27-0.13 ± 0.22-0.05 ± 0.33
Change from BL at FU0.30 ± 0.26-0.05 ± 0.300.18 ± 0.290.18 ± 0.08
PrimaryChange From Baseline in Chemistry Laboratory Test Results by Time Point: Thyroxine (T4). MAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline, Day 3, Day 8, FU (one week after last dosing)
Reported as:
Mean · ng/dL
Change From Baseline in Chemistry Laboratory Test Results by Time Point: Thyroxine (T4). MAD Group
ng/dLMAD Group IIIMAD Group IVMAD Group VPlacebo
Baseline (pre-dose Day 1)1.20 ± 0.081.25 ± 0.061.20 ± 0.181.07 ± 0.14
Change from BL at Day 30.05 ± 0.060.02 ± 0.050.05 ± 0.060.03 ± 0.08
Change from BL at Day 80.12 ± 0.050.07 ± 0.100.23 ± 0.100.17 ± 0.10
Change from BL at FU0.12 ± 0.050.03 ± 0.100.12 ± 0.050.10 ± 0.06
PrimaryChange From Baseline in Chemistry Laboratory Test Results by Time Point: Bicarbonate. MAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline, Day 3, Day 8, FU (one week after last dosing)
Reported as:
Mean · mmol/L
Change From Baseline in Chemistry Laboratory Test Results by Time Point: Bicarbonate. MAD Group
mmol/LMAD Group IIIMAD Group IVMAD Group VPlacebo
Baseline (pre-dose Day 1)27.53 ± 0.5425.53 ± 0.9228.53 ± 0.5927.23 ± 0.87
Change from BL at Day 3-0.38 ± 0.792.20 ± 1.510.10 ± 1.550.03 ± 1.40
Change from BL at Day 8-1.10 ± 1.621.42 ± 1.59-0.55 ± 1.720.47 ± 1.69
Change from BL at FU-1.18 ± 0.691.68 ± 1.27-0.32 ± 1.78-0.27 ± 1.87
PrimaryChange From Baseline in Chemistry Laboratory Test Results by Time Point: Lactate. MAD Group

Blood samples were collected from participants at the indicated timepoints for evaluation of chemistry parameters. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value.

Time frame:
Baseline, Day 3, Day 8, FU (one week after last dosing)
Reported as:
Mean · mg/dL
Change From Baseline in Chemistry Laboratory Test Results by Time Point: Lactate. MAD Group
mg/dLMAD Group IIIMAD Group IVMAD Group VPlacebo
Baseline (pre-dose Day 1)8.63 ± 4.267.00 ± 1.827.23 ± 1.089.12 ± 1.94
Change from BL at Day 30.98 ± 1.062.23 ± 4.011.18 ± 1.415.93 ± 6.62
Change from BL at Day 83.13 ± 3.002.30 ± 2.081.83 ± 1.561.23 ± 3.66
Change from BL at FU2.75 ± 3.301.08 ± 1.496.63 ± 4.95-0.12 ± 4.07
PrimaryPhospholipidosis

Change from Day 1 to Day 7 in di-docosahexaenoyl (22:6)-bis(monoacylglycerol) phosphate (di-22:6-BMP) and normalized di-22:6-BMP (urine) - MAD

Time frame:
Day 1, Day 7
Reported as:
Mean · ng/mL
Phospholipidosis
ng/mLMAD Group IIIMAD Group IVMAD Group VPlacebo
di-22:6-BMP: Change from Day 1 to Day 7-1.473 ± 4.520-3.465 ± 4.870-2.630 ± 2.633-1.592 ± 3.283
Normalized di-22:6-BMP: Change from Day 1 to Day 71.298 ± 0.8190.060 ± 1.1520.337 ± 1.1201.780 ± 1.874
PrimaryMAD: Change From Baseline in ECG Results by Time Point: Corrected QT Interval According to Barret's Formaula (QTcB)

The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation the average of the 3 recordings will be taken as baseline. Other ECG recordings will be singlet (one recording of at least 3 complexes) prior to dosing, or around the expected Cmax on Day 1 or 7 for the multiple- dose part.

Time frame:
Baseline (pre-dose Day 1), Day1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Follow-up
Reported as:
Mean · msec
MAD: Change From Baseline in ECG Results by Time Point: Corrected QT Interval According to Barret's Formaula (QTcB)
msecMAD Group IIIMAD Group IVMAD Group VPlacebo
Baseline (Pre-dose Day 1)391.3 ± 10.8381.0 ± 28.9384.0 ± 11.0385.2 ± 15.4
Change from baseline at 2h - Day 13.8 ± 10.312.3 ± 8.811.8 ± 9.70.7 ± 6.9
Change from BL at 24h - Day 1-1.0 ± 9.80.3 ± 6.211.5 ± 19.2-5.7 ± 9.7
Baseline (pre-dose Day 7)398.3 ± 7.9386.5 ± 26.1402.0 ± 6.6378.8 ± 13.3
Change from pre-dose Day 7 at 1h - Day 7-3.8 ± 9.1-3.8 ± 7.9-10.3 ± 11.1-3.5 ± 6.0
Change from pre-dose Day 7 at 2h - Day 7-5.0 ± 4.25.8 ± 15.22.5 ± 8.71.0 ± 16.2
Change from pre-dose Day 7 at 4h-7.8 ± 7.7-3.8 ± 6.2-6.5 ± 13.9-0.5 ± 12.1
Change from pre-dose Day 7 BL at 6h - Day 75.3 ± 9.812.5 ± 7.0-1.8 ± 8.35.8 ± 23.5
Change from pre-dose Day 7 at 8h - Day 7-7.0 ± 2.8-4.5 ± 9.7-11.5 ± 7.23.0 ± 6.9
Change from pre-dose Day 7 at 12h - Day 74.5 ± 11.43.0 ± 5.0-9.0 ± 8.16.7 ± 5.7
Change from BL at pre-dose Day 2-1.0 ± 9.80.3 ± 6.211.5 ± 19.2-5.7 ± 9.7
Change from BL at pre-dose Day 36.0 ± 14.10.5 ± 9.720.5 ± 22.3-8.5 ± 5.8
Change from BL at pre-dose Day 46.5 ± 11.52.0 ± 14.77.5 ± 17.1-10.2 ± 5.0
Change from BL at pre-dose Day 513.8 ± 14.310.3 ± 4.314.0 ± 14.2-8.5 ± 5.6
Change from BL at pre-dose Day 65.5 ± 9.9-2.3 ± 6.713.5 ± 13.8-10.5 ± 14.5
Change from BL at pre-dose Day 77.0 ± 6.55.5 ± 9.618.0 ± 9.2-11.3 ± 7.7
Change from BL at FU7.8 ± 9.711.0 ± 3.210.5 ± 24.43.8 ± 14.3
PrimaryMAD: Change From Baseline in ECG Results by Time Point: P Wave-Q Wave Interval (PQ Interval)

The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation of the PQ interval the average of the 3 recordings will be taken as baseline.

Time frame:
Baseline (pre-dose Day 1), Day1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Follow-up
Reported as:
Mean · msec
MAD: Change From Baseline in ECG Results by Time Point: P Wave-Q Wave Interval (PQ Interval)
msecMAD Group IIIMAD Group IVMAD Group VPlacebo
Baseline (Pre-dose Day 1)185.8 ± 33.4160.5 ± 18.5162.0 ± 7.0171.8 ± 20.0
Change from baseline at 2h - Day 12.8 ± 2.8-1.5 ± 3.06.0 ± 5.06.2 ± 10.3
Change from BL at 24h - Day 1-5.8 ± 6.1-0.5 ± 1.92.0 ± 6.6-6.5 ± 14.0
Baseline (pre-dose Day 7)191.5 ± 33.4164.0 ± 22.9167.5 ± 5.3178.3 ± 11.8
Change from pre-dose Day 7 at 1h - Day 7-1.0 ± 4.85.5 ± 306.5 ± 2.5-1.7 ± 2.0
Change from pre-dose Day 7 at 2h - Day 7-3.5 ± 5.7-1.5 ± 3.44.0 ± 4.3-14.7 ± 14.7
Change from pre-dose Day 7 at 4h-9.0 ± 9.0-1.0 ± 3.80.0 ± 1.6-14.3 ± 15.0
Change from pre-dose Day 7 BL at 6h - Day 7-13.0 ± 4.8-3.5 ± 8.2-4.5 ± 2.5-6.7 ± 5.2
Change from pre-dose Day 7 at 8h - Day 7-10.0 ± 5.90.0 ± 7.3-5.0 ± 2.6-11.3 ± 4.1
Change from pre-dose Day 7 at 12h - Day 7-24.0 ± 23.6-1.5 ± 5.7-4.5 ± 4.1-4.0 ± 7.6
Change from BL at pre-dose Day 2-5.8 ± 6.1-0.5 ± 1.92.0 ± 6.6-6.5 ± 14.0
Change from BL at pre-dose Day 36.3 ± 5.44.5 ± 2.50.0 ± 6.8-6.8 ± 7.3
Change from BL at pre-dose Day 46.3 ± 3.39.5 ± 1.07.5 ± 6.8-3.8 ± 19.7
Change from BL at pre-dose Day 5-2.3 ± 7.44.0 ± 6.28.5 ± 10.1-2.2 ± 16.9
Change from BL at pre-dose Day 6-0.3 ± 9.53.0 ± 4.36.0 ± 3.55.2 ± 19.0
Change from BL at pre-dose Day 75.8 ± 6.83.5 ± 5.75.5 ± 5.76.5 ± 20.9
Change from BL at FU-6.8 ± 12.0-2.5 ± 3.4-3.5 ± 6.40.5 ± 16.2
PrimaryMAD: Change From Baseline in ECG Results by Time Point: the Interval That Denotes Depolarization of the Ventricles, Between the Beginning of the Q Wave and the End of the S Wave (QRS Interval)

The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation the average of the 3 recordings will be taken as baseline. Other ECG recordings will be singlet (one recording of at least 3 complexes) prior to dosing, or around the expected Cmax on Day 1 or 7 for the multiple- dose part.

Time frame:
Baseline (pre-dose Day 1), Day1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Follow-up
Reported as:
Mean · msec
MAD: Change From Baseline in ECG Results by Time Point: the Interval That Denotes Depolarization of the Ventricles, Between the Beginning of the Q Wave and the End of the S Wave (QRS Interval)
msecMAD Group IIIMAD Group IVMAD Group VPlacebo
Baseline (Pre-dose Day 1)99.3 ± 6.992.5 ± 6.185.5 ± 8.398.5 ± 8.2
Change from BL at 2h - Day 11.3 ± 1.02.0 ± 1.46.0 ± 2.9-0.2 ± 1.8
Change from BL at 24h - Day 10.3 ± 2.12.5 ± 2.43.5 ± 2.6-0.8 ± 1.3
Baseline (pre-dose Day 7)99.5 ± 7.297.0 ± 5.387.5 ± 7.298.7 ± 8.8
Change from BL Day 7 at 1h - Day 70.5 ± 3.00.0 ± 2.85.0 ± 2.0-0.3 ± 0.8
Change from BL Day 7 at 2h - Day 70.5 ± 1.91.0 ± 1.25.5 ± 1.90.7 ± 2.4
Change from BL Day 7 at 4h0.0 ± 2.8-0.5 ± 1.02.5 ± 2.50.7 ± 3.0
Change from BL Day 7 BL at 6h - Day 70.5 ± 1.9-2.5 ± 2.53.0 ± 2.00.7 ± 2.4
Change from BL Day 7 at 8h - Day 7-3.5 ± 1.9-0.5 ± 1.92.0 ± 1.60.7 ± 4.8
Change from BL Day 7 at 12h - Day 7-1.5 ± 3.0-2.0 ± 1.62.0 ± 0.0-2.0 ± 3.6
Change from BL at pre-dose Day 20.3 ± 2.12.5 ± 2.43.5 ± 2.6-0.8 ± 1.3
Change from BL at pre-dose Day 30.3 ± 2.12.5 ± 1.32.0 ± 3.7-0.8 ± 2.4
Change from BL at pre-dose Day 4-0.8 ± 1.55.0 ± 3.43.5 ± 1.7-0.5 ± 2.7
Change from BL at pre-dose Day 5-0.8 ± 1.52.5 ± 0.62.5 ± 1.7-0.5 ± 2.7
Change from BL at pre-dose Day 6-0.3 ± 1.32.0 ± 2.41.0 ± 2.2-1.8 ± 2.0
Change from BL at pre-dose Day 70.3 ± 0.54.5 ± 1.32.0 ± 1.40.2 ± 3.1
Change from BL at FU0.3 ± 2.60.5 ± 1.7-2.5 ± 2.4-1.8 ± 5.2
PrimaryMAD: Change From Baseline in ECG Results by Time Point: QT Interval

The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation the average of the 3 recordings will be taken as baseline. Other ECG recordings will be singlet (one recording of at least 3 complexes) prior to dosing, or around the expected Cmax on Day 1 or 7 for the multiple- dose part.

Time frame:
Baseline (pre-dose Day 1), Day1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Follow-up
Reported as:
Mean · msec
MAD: Change From Baseline in ECG Results by Time Point: QT Interval
msecMAD Group IIIMAD Group IVMAD Group VPlacebo
Baseline (Pre-dose Day 1)410.5 ± 41.8391.5 ± 8.5399.0 ± 11.2410.2 ± 33.0
Change from BL at 2h - Day 1-5.5 ± 10.5-7.5 ± 16.0-4.0 ± 3.74.2 ± 10.1
Change from BL at 24h - Day 1-10.0 ± 11.91.0 ± 8.8-14.5 ± 4.8-4.2 ± 14.6
Baseline (pre-dose Day 7)393.0 ± 42.6388.5 ± 20.6402.0 ± 18.8406.0 ± 22.9
Change from pre-dose Day 7 at 1h - Day 75.0 ± 12.4-1.0 ± 7.40.0 ± 9.11.0 ± 8.1
Change from pre-dose Day 7 at 2h - Day 70.0 ± 6.5-10.5 ± 15.4-7.5 ± 10.0-2.3 ± 14.2
Change from pre-dose Day 7 at 4h-7.0 ± 1.2-2.0 ± 7.1-4.0 ± 11.910.7 ± 15.9
Change from pre-dose Day 7 BL at 6h - Day 7-15.5 ± 14.2-17.0 ± 15.2-16.5 ± 10.6-14.3 ± 26.8
Change from pre-dose Day 7 at 8h - Day 7-18.5 ± 13.7-1.0 ± 12.7-11.0 ± 11.9-3.0 ± 17.9
Change from pre-dose Day 7 at 12h - Day 7-20.0 ± 14.1-20.0 ± 6.3-11.5 ± 9.6-8.7 ± 19.9
Change from BL at pre-dose Day 2-10.0 ± 11.91.0 ± 8.8-14.5 ± 4.8-4.2 ± 14.6
Change from BL at pre-dose Day 3-10.5 ± 20.07.5 ± 6.6-10.0 ± 9.6-6.2 ± 12.6
Change from BL at pre-dose Day 4-6.0 ± 26.1-3.5 ± 13.46.0 ± 4.5-0.2 ± 20.7
Change from BL at pre-dose Day 5-9.0 ± 24.9-13.0 ± 11.93.0 ± 9.41.2 ± 16.1
Change from BL at pre-dose Day 6-16.0 ± 23.5-0.5 ± 12.2-4.5 ± 10.1-3.8 ± 11.9
Change from BL at pre-dose Day 7-17.5 ± 32.3-3.0 ± 14.83.0 ± 9.4-4.2 ± 16.1
Change from BL at FU-22.0 ± 13.2-10.5 ± 14.6-23.0 ± 14.313.2 ± 23.9
PrimarySAD: Change From Baseline in ECG Results by Time Point: PQ Interval

The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation the average of the 3 recordings will be taken as baseline.

Time frame:
Pre-dose, Day 1, Day 7
Reported as:
Mean · msec
SAD: Change From Baseline in ECG Results by Time Point: PQ Interval
msecSAD Group I PlaceboSAD Group II PlaceboSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I Placebo + FoodGroup II 100mg + Food
Baseline (Pre-dose Day 1)195.5 ± 28.9165.0 ± 21.6154.5 ± 39.2159.8 ± 23.0155.0 ± 24.4176.5 ± 21.4171.8 ± 15.9176.0 ± 17.7177.0 ± 26.9147.5 ± 25.2
Change from baseline at 1h-1.2 ± 4.03.3 ± 7.4-0.5 ± 1.9-1.3 ± 5.7-4.0 ± 3.74.0 ± 2.88.8 ± 3.020.5 ± 7.5-9.0 ± 9.9-3.5 ± 4.4
Change from BL at 2h post dose1.2 ± 3.9-0.7 ± 3.7-3.0 ± 3.71.3 ± 3.8-3.0 ± 3.84.5 ± 5.78.3 ± 11.816.0 ± 5.9-11.0 ± 9.9-1.0 ± 2.6
Change from BL at 4h post dose-1.5 ± 8.8-2.3 ± 0.8-2.0 ± 2.64.8 ± 4.4-3.5 ± 5.30.0 ± 4.03.3 ± 5.710.0 ± 6.3-5.0 ± 7.1-1.5 ± 3.0
Change from BL at 6h post dose-1.2 ± 3.6-2.7 ± 3.3-2.0 ± 2.60.8 ± 7.2-7.5 ± 5.3-5.5 ± 8.5-3.3 ± 8.89.0 ± 6.0-11.0 ± 12.7-1.5 ± 1.9
Change from BL at 8h post dose-3.2 ± 3.61.0 ± 6.2-6.5 ± 5.5-1.3 ± 7.4-8.0 ± 4.3-8.0 ± 8.6-5.3 ± 7.81.0 ± 10.4-6.0 ± 2.8-4.0 ± 3.7
Change from BLat 12h post dose-1.8 ± 4.7-3.7 ± 8.3-4.0 ± 4.8-1.8 ± 4.9-6.5 ± 4.4-9.5 ± 10.6-4.3 ± 5.70.5 ± 7.7-9.0 ± 12.7-1.5 ± 4.7
Change from BL at 24h post dose-2.2 ± 3.3-3.7 ± 8.5-4.5 ± 8.4-4.3 ± 2.6-7.0 ± 3.5-6.5 ± 3.0-4.3 ± 4.9-5.5 ± 8.90.0 ± 0.0-2.0 ± 2.8
Change from BL at FU-5.5 ± 4.9-1.3 ± 7.4-5.0 ± 4.3-7.3 ± 2.2-11.0 ± 5.3-3.0 ± 9.3-9.8 ± 4.9-7.0 ± 2.6-16.0 ± 14.1-3.5 ± 5.0
PrimarySAD: Change From Baseline in ECG Results by Time Point: QRS Interval

The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation the average of the 3 recordings will be taken as baseline.

Time frame:
Pre-dose, Day 1, Day 7
Reported as:
Mean · msec
SAD: Change From Baseline in ECG Results by Time Point: QRS Interval
msecSAD Group I PlaceboSAD Group II PlaceboSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I Placebo + FoodGroup II 100mg + Food
Baseline (Pre-dose Day 1)103.0 ± 8.397.0 ± 9.699.3 ± 3.397.8 ± 7.6106.5 ± 10.292.5 ± 13.9104.5 ± 10.694.0 ± 8.895.0 ± 7.1105.5 ± 8.3
Change from baseline at 1h-0.7 ± 2.01.0 ± 5.2-1.3 ± 0.50.3 ± 2.20.0 ± 2.83.5 ± 3.41.5 ± 6.426.0 ± 6.91.0 ± 1.40.0 ± 2.8
Change from BL at 2h post dose-2.0 ± 3.00.7 ± 3.2-1.3 ± 1.3-0.3 ± 1.0-2.5 ± 1.03.0 ± 2.62.5 ± 7.220.5 ± 7.70.0 ± 0.0-2.0 ± 2.8
Change from BL at 4h post dose-1.0 ± 3.0-0.7 ± 2.2-1.3 ± 1.7-0.8 ± 0.5-2.0 ± 0.02.0 ± 2.82.5 ± 3.017.0 ± 6.00.0 ± 2.8-3.5 ± 3.4
Change from BL at 6h post dose0.3 ± 3.80.3 ± 1.60.8 ± 2.6-0.3 ± 2.8-1.5 ± 1.03.5 ± 2.51.5 ± 2.514.5 ± 5.31.0 ± 1.4-1.5 ± 3.4
Change from BL at 8h post dose-2.0 ± 2.8-1.0 ± 1.31.3 ± 3.3-0.8 ± 2.1-2.0 ± 1.62.5 ± 1.90.0 ± 6.713.0 ± 4.80.0 ± 0.0-0.5 ± 1.9
Change from BL at 12h post dose-0.7 ± 3.6-1.7 ± 1.00.3 ± 2.5-0.3 ± 2.5-1.5 ± 2.51.0 ± 2.62.5 ± 3.07.0 ± 2.00.0 ± 0.0-2.5 ± 3.0
Change from BL at 24h post dose-2.7 ± 5.3-1.7 ± 3.4-1.3 ± 0.5-2.3 ± 2.2-1.5 ± 1.91.5 ± 4.40.0 ± 1.64.0 ± 0.0-3.0 ± 4.2-1.0 ± 2.0
Change from BL at FU-1.3 ± 6.2-0.7 ± 4.4-1.3 ± 3.50.8 ± 6.4-2.5 ± 4.10.0 ± 3.3-3.0 ± 5.3-0.5 ± 2.5-1.0 ± 4.2-1.5 ± 4.7
PrimarySAD: Change From Baseline in ECG Results by Time Point: QT Interval

The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation the average of the 3 recordings will be taken as baseline.

Time frame:
Pre-dose, Day 1, Day 7
Reported as:
Mean · msec
SAD: Change From Baseline in ECG Results by Time Point: QT Interval
msecSAD Group I PlaceboSAD Group II PlaceboSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I Placebo + FoodGroup II 100mg + Food
Baseline (Pre-dose Day 1)400.0 ± 18.6415.0 ± 23.5393.3 ± 15.4416.0 ± 15.6404.0 ± 11.4409.0 ± 28.2396.3 ± 15.9398.3 ± 17.3373.0 ± 7.1396.0 ± 12.8
Change from baseline at 1h9.7 ± 12.7-4.3 ± 13.62.3 ± 6.4-8.5 ± 9.510.5 ± 5.3-3.0 ± 7.4-5.8 ± 17.68.8 ± 22.7-11.0 ± 1.4-15.5 ± 14.3
Change from BL at 2h post dose3.0 ± 8.5-7.3 ± 16.24.8 ± 21.40.5 ± 9.79.0 ± 10.9-2.5 ± 6.63.3 ± 17.14.8 ± 21.9-2.0 ± 5.716.0 ± 11.7
Change from BL at 4h post dose9.3 ± 7.5-3.7 ± 16.93.3 ± 9.06.0 ± 7.17.0 ± 12.9-2.0 ± 11.4-3.8 ± 16.71.8 ± 14.67.0 ± 4.2-4.0 ± 8.5
Change from BL at 6h post dose-6.7 ± 8.8-16.0 ± 14.8-9.8 ± 8.5-19.5 ± 7.4-3.5 ± 13.2-11.0 ± 6.2-19.3 ± 9.2-4.8 ± 16.3-14.0 ± 5.7-13.0 ± 8.4
Change from BL at 8h post dose-8.7 ± 4.4-24.0 ± 9.9-6.8 ± 9.1-18.5 ± 4.0-4.0 ± 16.6-16.0 ± 9.8-14.8 ± 9.3-5.3 ± 7.1-17.0 ± 15.6-9.0 ± 9.3
Change from BL at 12h post dose-8.7 ± 3.3-24.3 ± 16.3-2.8 ± 9.0-15.5 ± 11.2-6.5 ± 13.0-22.5 ± 6.8-12.3 ± 7.5-13.3 ± 15.9-18.0 ± 17.0-10.0 ± 15.5
Change from BL at 24h post dose-6.7 ± 6.1-23.0 ± 13.5-11.8 ± 3.0-15.5 ± 16.5-4.5 ± 8.2-17.0 ± 14.7-10.3 ± 13.32.3 ± 4.9-3.0 ± 18.4-7.0 ± 3.8
Change from BL at FU-12.0 ± 4.3-18.3 ± 11.4-13.8 ± 6.7-12.5 ± 9.8-9.0 ± 5.0-12.0 ± 13.4-8.3 ± 12.4-7.8 ± 10.1-2.0 ± 25.5-1.0 ± 8.9
PrimarySAD: Change From Baseline in ECG Results by Time Point: QTcB Interval

The baseline ECG recording consists of a triplicate recording (3 recordings of a least 3 complexes within a 5 minute window) prior to dosing on Day 1. For the evaluation the average of the 3 recordings will be taken as baseline.

Time frame:
Pre-dose, Day1, Day 7
Reported as:
Mean · msec
SAD: Change From Baseline in ECG Results by Time Point: QTcB Interval
msecSAD Group I PlaceboSAD Group II PlaceboSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I Placebo + FoodGroup II 100mg + Food
Baseline (Pre-dose Day 1)379.3 ± 21.0385.5 ± 9.8382.0 ± 21.4390.5 ± 8.9383.8 ± 24.8386.3 ± 8.0382.0 ± 10.9378.5 ± 19.1367.5 ± 24.7382.3 ± 22.0
Change from BL at 1h1.7 ± 7.7-0.7 ± 10.1-1.0 ± 2.8-0.3 ± 6.7-3.5 ± 5.01.8 ± 7.33.0 ± 8.639.0 ± 19.012.5 ± 29.016.0 ± 7.9
Change from BL at 2h post dose-0.5 ± 12.8-2.8 ± 9.3-4.0 ± 18.2-6.5 ± 7.9-10.8 ± 9.63.0 ± 8.49.8 ± 8.341.3 ± 21.74.5 ± 25.310.3 ± 4.0
Change from BL at 4h post dose5.5 ± 15.2-1.5 ± 17.1-7.3 ± 3.3-8.3 ± 11.9-1.5 ± 7.06.0 ± 17.86.5 ± 6.238.5 ± 10.79.0 ± 28.31.8 ± 8.2
Change from BL at 6h post dose12.7 ± 4.83.7 ± 8.411.5 ± 5.84.0 ± 13.10.0 ± 14.914.0 ± 11.017.8 ± 1.041.8 ± 13.820.0 ± 15.615.5 ± 6.6
Change from BL at 8h post dose3.0 ± 12.31.2 ± 9.3-4.8 ± 7.86.8 ± 14.28.5 ± 18.75.5 ± 12.18.0 ± 7.437.5 ± 19.35.0 ± 12.75.0 ± 6.5
Change from BL at 12h post dose7.0 ± 8.33.8 ± 8.9-1.0 ± 2.2-2.8 ± 14.02.8 ± 13.011.5 ± 13.117.8 ± 5.236.0 ± 9.417.5 ± 2.19.5 ± 10.3
Change from BL at 24h post dose11.7 ± 19.30.0 ± 8.60.0 ± 11.30.8 ± 15.13.0 ± 7.11.5 ± 6.55.3 ± 9.015.8 ± 4.9-0.5 ± 21.9-2.5 ± 5.7
Change from BL at FU5.3 ± 17.613.0 ± 15.44.8 ± 18.810.8 ± 15.98.3 ± 19.813.3 ± 12.7-3.5 ± 6.59.0 ± 14.49.0 ± 28.39.8 ± 18.5
PrimaryTerminal Elimination Half-life (T1/2) of KH176 Over 24 Hours: SAD

Plasma concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.

Time frame:
Pre-dose (5 min before dosing) and 0.5, 1, 1.5, 2, 3, 6, 8, 12, and 24 hours post-dose
Reported as:
Geometric mean · hours
Terminal Elimination Half-life (T1/2) of KH176 Over 24 Hours: SAD
hoursSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I 100mg + Food
Terminal Elimination Half-life (T1/2) of KH176 Over 24 Hours: SAD0 ± 010.3 ± 14.69.10 ± 15.29.64 ± 4.299.80 ± 19.111.5 ± 4.739.09 ± 3.83
PrimaryTerminal Elimination Half-life (T1/2) of KH183: SAD

Plasma concentrations of KH183 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food) , 300mg, 800mg, 2000mg b.i.d.

Time frame:
Pre-dose (5 min before dosing) and 0.5, 1, 1.5, 2, 3, 6, 8, 12, and 24 hours post-dose
Reported as:
Geometric mean · hours
Terminal Elimination Half-life (T1/2) of KH183: SAD
hoursSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I 100mg + Food
Terminal Elimination Half-life (T1/2) of KH183: SAD16.6 ± 5.8617.8 ± 19.015.4 ± 8.4414.3 ± 18.917.2 ± 18.518.9 ± 18.714.9 ± 7.86
PrimaryMaximum Concentration (Cmax) of KH176: SAD Group

Plasma concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.

Time frame:
Pre-dose (5 min before dosing) and 0.5, 1, 1.5, 2, 3, 6, 8, 12, and 24 hours post-dose
Reported as:
Geometric mean · ng/mL
Maximum Concentration (Cmax) of KH176: SAD Group
ng/mLSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I 100mg + Food
Maximum Concentration (Cmax) of KH176: SAD Group12.9 ± 21.356.2 ± 21.0167 ± 27.2766 ± 53.92170 ± 27.95990 ± 20.9165 ± 7.40
PrimaryMaximum Concentration (Cmax) of KH183 Over 24 Hours: SAD

Plasma concentrations of KH183 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food) , 300mg, 800mg, 2000mg b.i.d.

Time frame:
Pre-dose (5 min before dosing) and 0.5, 1, 1.5, 2, 3, 6, 8, 12, and 24 hours post-dose
Reported as:
Geometric mean · ng/mL
Maximum Concentration (Cmax) of KH183 Over 24 Hours: SAD
ng/mLSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I 100mg + Food
Maximum Concentration (Cmax) of KH183 Over 24 Hours: SAD14.2 ± 49.549.4 ± 9.00168 ± 29.6497 ± 17.61100 ± 9.581780 ± 26.3117 ± 20.0
PrimaryMaximum Concentration (Cmax) of KH183 (Active Metabolite of KH176): MAD Group

Plasma concentrations of KH183 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.: Cmax was obtained directly from the concentration-time data.

Time frame:
Predose at Day 1, 2, 4, 7, and post-dose at Day 1 and Day 7 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours
Reported as:
Geometric mean · ng/mL
Maximum Concentration (Cmax) of KH183 (Active Metabolite of KH176): MAD Group
ng/mLCmax Dose 100mgCmax - Dose 200mgCmax - Dose 400mg
Day 199.4 ± 20.9251 ± 18.0550 ± 14.1
Day 7152 ± 37.5250 ± 10.6450 ± 28.3
PrimaryMaximum Concentration (Cmax) of KH176: MAD

Plasma concentrations of KH176 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.

Time frame:
pre-dose at Day 1, 2, 4, 7, and post-dose at Day 1 and Day 7 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours
Reported as:
Geometric mean · ng/mL
Maximum Concentration (Cmax) of KH176: MAD
ng/mLCmax Dose 100mgCmax - Dose 200mgCmax - Dose 400mg
Day 1184 ± 57.0313 ± 20.01330 ± 27.3
Day 7353 ± 19.1748 ± 29.32100 ± 27.2
PrimaryTime to Maximum Concentration (Tmax) of KH176 Over 24 Hours: SAD

Plasma concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.

Time frame:
Pre-dose (5 min before dosing) and 0.5, 1, 1.5, 2, 3, 6, 8, 12, and 24 hours post-dose
Reported as:
Geometric mean · hours
Time to Maximum Concentration (Tmax) of KH176 Over 24 Hours: SAD
hoursSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I 100mg + Food
Time to Maximum Concentration (Tmax) of KH176 Over 24 Hours: SAD1.03 ± 55.51.03 ± 55.50.931 ± 83.41.10 ± 85.61.36 ± 20.50.931 ± 1022.45 ± 23.7
PrimaryTime to Reach Peak Plasma Concentration (Tmax) of KH183: SAD

Plasma concentrations of KH183 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.

Time frame:
Pre-dose (5 min before dosing) and 0.5, 1, 1.5, 2, 3, 6, 8, 12, and 24 hours post-dose
Reported as:
Geometric mean · ng/mL
Time to Reach Peak Plasma Concentration (Tmax) of KH183: SAD
ng/mLSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I 100mg + Food
Time to Reach Peak Plasma Concentration (Tmax) of KH183: SAD1.32 ± 34.81.46 ± 29.11.32 ± 34.81.31 ± 34.71.61 ± 14.51.57 ± 33.72.45 ± 23.7
PrimaryTime to Maximum Concentration (Tmax) of KH176 at Day 1, Day 7: MAD Group

Plasma concentrations of KH176 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.

Time frame:
pre-dose at Day 1, 2, 4, 7, and post-dose at Day 1 and Day 7 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours
Reported as:
Geometric mean · hours
Time to Maximum Concentration (Tmax) of KH176 at Day 1, Day 7: MAD Group
hoursTmax Dose 100mgTmax - Dose 200mgTmax - Dose 400mg
Day 11.57 ± 1731.73 ± 16.70.866 ± 70.4
Day 70.931 ± 48.11.86 ± 14.51.36 ± 85.5
PrimaryTime to Maximum Concentration (Tmax) of KH183 (Active Metabolite of KH176): MAD Group

Plasma concentrations of KH183 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.. tmax was obtained directly from the concentration-time data.

Time frame:
Predose at Day 1, 2, 4, 7, and post-dose at Day 1 and Day 7 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours
Reported as:
Geometric mean · hours
Time to Maximum Concentration (Tmax) of KH183 (Active Metabolite of KH176): MAD Group
hoursTmax Dose 100mgTmax - Dose 200mgTmax - Dose 400mg
Day 12.06 ± 1161.57 ± 33.71.22 ± 23.7
Day 71.19 ± 36.61.46 ± 29.11.61 ± 48.1
PrimaryAccumulation Factor (Racc) of KH176 Over 7 Days: MAD Group

Plasma concentrations of KH176 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.. Racc was calculated as follows: AUCtau day 7/ AUCtau day 1.

Time frame:
Pre-dose at Day 1, 2, 4, 7, and post-dose at Day 1 and Day 7 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours
Reported as:
Geometric mean · ratio
Accumulation Factor (Racc) of KH176 Over 7 Days: MAD Group
ratioRacc Dose 100mgRacc- Dose 200mgRacc - Dose 400mg
Accumulation Factor (Racc) of KH176 Over 7 Days: MAD Group2.52 ± 31.22.65 ± 2.52.17 ± 14.4
PrimaryAccumulation Factor (Racc) of KH183 (Active Metabolite of KH176): MAD Group

Plasma concentrations of KH183 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.: Accumulation factor was calculated as follows: AUCtau day 7/ AUCtau day 1.

Time frame:
Predose at Day 1, 2, 4, 7, and post-dose at Day 1 and Day 7 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours
Reported as:
Geometric mean · ratio
Accumulation Factor (Racc) of KH183 (Active Metabolite of KH176): MAD Group
ratioRacc Dose 100mgRacc- Dose 200mgRacc - Dose 400mg
Accumulation Factor (Racc) of KH183 (Active Metabolite of KH176): MAD Group1.86 ± 46.71.32 ± 13.11.19 ± 24.7
PrimaryArea Under the Plasma Concentration Versus Time Curve (AUClast) of KH183: SAD Group

Plasma concentrations of KH183 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food) , 300mg, 800mg, 2000mg b.i.d.

Time frame:
Pre-dose (5 min before dosing) and 0.5, 1, 1.5, 2, 3, 6, 8, 12, and 24 hours post-dose
Reported as:
Geometric mean · h*ng/mL
Area Under the Plasma Concentration Versus Time Curve (AUClast) of KH183: SAD Group
h*ng/mLSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I 100mg + Food
Area Under the Plasma Concentration Versus Time Curve (AUClast) of KH183: SAD Group151 ± 26.7547 ± 12.41810 ± 37.44830 ± 11.811700 ± 20.223900 ± 22.21590 ± 26.1
PrimaryArea Under the Plasma Concentration Versus Time Curve (AUClast) of KH176: SAD Group

Plasma concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.

Time frame:
pre-dose (5 min before dosing) and 0.5, 1, 1.5, 2, 3, 6, 8, 12, and 24 hours post-dose
Reported as:
Geometric mean · h*ng/mL
Area Under the Plasma Concentration Versus Time Curve (AUClast) of KH176: SAD Group
h*ng/mLSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I 100mg + Food
Area Under the Plasma Concentration Versus Time Curve (AUClast) of KH176: SAD Group75 ± 14.8389 ± 8.161310 ± 16.76320 ± 20.221000 ± 27.561200 ± 9.071650 ± 1.67
PrimaryArea Under the Plasma Concentration-time Curve (AUCtau) of KH176: MAD Group:

Plasma concentrations of KH176 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.

Time frame:
Pre-dose at Day 1, 2, 4, 7, and post-dose at Day 1 and Day 7 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours
Reported as:
Geometric mean · h*ng/mL
Area Under the Plasma Concentration-time Curve (AUCtau) of KH176: MAD Group:
h*ng/mLAUCtau Dose 100mgAUCtau - Dose 200mgAUCtau - Dose 400mg
Day 11090 ± 49.32250 ± 26.16890 ± 19.2
Day 72760 ± 22.65960 ± 26.814900 ± 28.2
PrimaryArea Under the Plasma Concentration-time Curve During a Dose Interval (AUCtau) of KH183 (Active Metabolite of KH176): MAD Group

Plasma concentrations of KH183 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.

Time frame:
Predose at Day 1, 2, 4, 7, and post-dose at Day 1 and Day 7 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours
Reported as:
Geometric mean · h*ng/mL
Area Under the Plasma Concentration-time Curve During a Dose Interval (AUCtau) of KH183 (Active Metabolite of KH176): MAD Group
h*ng/mLAUCtau Dose 100mgAUCtau - Dose 200mgAUCtau - Dose 400mg
Day 1702 ± 29.21680 ± 21.03600 ± 11.1
Day 71310 ± 29.52220 ± 12.74270 ± 30.5
PrimaryArea Under the Plasma Concentration-time Curve From Time Zero Until Infinity (AUCl0-inf) of KH183: SAD

Plasma concentrations of KH183 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food) , 300mg, 800mg, 2000mg b.i.d.

Time frame:
Pre-dose (5 min before dosing) and 0.5, 1, 1.5, 2, 3, 6, 8, 12, and 24 hours post-dose
Reported as:
Geometric mean · h*ng/mL
Area Under the Plasma Concentration-time Curve From Time Zero Until Infinity (AUCl0-inf) of KH183: SAD
h*ng/mLSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I 100mg + Food
Area Under the Plasma Concentration-time Curve From Time Zero Until Infinity (AUCl0-inf) of KH183: SAD234 ± 26.7881 ± 19.62690 ± 38.46690 ± 11.018700 ± 26.741300 ± 10.52410 ± 29.1
PrimaryArea Under the Plasma Concentration-time Curve From Time Zero Until Infinity (AUCl0-inf) of KH176: SAD

Plasma concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food) , 300mg, 800mg, 2000mg b.i.d.

Time frame:
Pre-dose (5 min before dosing) and 0.5, 1, 1.5, 2, 3, 6, 8, 12, and 24 hours post-dose
Reported as:
Geometric mean · h*ng/mL
Area Under the Plasma Concentration-time Curve From Time Zero Until Infinity (AUCl0-inf) of KH176: SAD
h*ng/mLSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I 100mg + Food
Area Under the Plasma Concentration-time Curve From Time Zero Until Infinity (AUCl0-inf) of KH176: SAD0 ± 0474 ± 8.391540 ± 13.17500 ± 19.125800 ± 33.979100 ± 8.821970 ± 1.04
PrimaryKH176: Percentage of Administered Dose Excreted in Urine: SAD

Urine concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.

Time frame:
24 hours post-dose
Reported as:
Geometric mean · percentage of dose excreted
KH176: Percentage of Administered Dose Excreted in Urine: SAD
percentage of dose excretedSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mg
KH176: Percentage of Administered Dose Excreted in Urine: SAD9.71 ± 37.410.5 ± 45.610.4 ± 29.59.53 ± 65.210.9 ± 41.612.4 ± 20.7
PrimaryKH183: Percentage of Administered Dose Excreted in Urine: SAD

Urine concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.

Time frame:
24 hours post-dose
Reported as:
Geometric mean · percentage of dose excreted
KH183: Percentage of Administered Dose Excreted in Urine: SAD
percentage of dose excretedSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mg
KH183: Percentage of Administered Dose Excreted in Urine: SAD4.56 ± 53.06.42 ± 14.55.18 ± 28.83.81 ± 82.93.86 ± 31.03.33 ± 32.8
PrimaryKH176 + KH183: Percentage of Administered Dose Excreted in Urine: SAD

Urine concentrations of KH176 were analysed after single dose administration of doses 10mg, 30mg, 100mg (with and without food), 300mg, 800mg, 2000mg b.i.d.

Time frame:
24 hours post-dose
Reported as:
Geometric mean · percentage of dose excreted
KH176 + KH183: Percentage of Administered Dose Excreted in Urine: SAD
percentage of dose excretedSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mg
KH176 + KH183: Percentage of Administered Dose Excreted in Urine: SAD14.4 ± 40.017.2 ± 28.615.8 ± 24.513.4 ± 69.914.8 ± 38.415.9 ± 16.4
PrimaryKH176: Percentage of Administered Dose Excreted in Urine: MAD

Urine concentrations of KH176 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.

Time frame:
Day 7 post dose
Reported as:
Geometric mean · percentage of dose excreted
KH176: Percentage of Administered Dose Excreted in Urine: MAD
percentage of dose excretedMAD Group Dose 100mgMAD Group - Dose 200mgMAD Group - Dose 400mg
KH176: Percentage of Administered Dose Excreted in Urine: MAD14.9 ± 77.813.4 ± 36.414.0 ± 14.5
PrimaryKH183: Percentage of Administered Dose Excreted in Urine: MAD

Urine concentrations of KH183 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.

Time frame:
Post dose Day 7
Reported as:
Geometric mean · percentage of dose excreted
KH183: Percentage of Administered Dose Excreted in Urine: MAD
percentage of dose excretedMAD Group Dose 100mgMAD Group - Dose 200mgMAD Group - Dose 400mg
KH183: Percentage of Administered Dose Excreted in Urine: MAD5.30 ± 120.23.79 ± 39.24.85 ± 43.8
PrimaryKH173 + KH183: Percentage of Administered Dose Excreted in Urine: MAD

Urine concentrations of KH176 and KH183 were analysed after multiple-dose administration of doses of 100, 200 and 400 mg b.i.d.

Time frame:
Day 7 Post dose
Reported as:
Geometric mean · percentage of dose excreted
KH173 + KH183: Percentage of Administered Dose Excreted in Urine: MAD
percentage of dose excretedMAD Group Dose 100mgMAD Group - Dose 200mgMAD Group - Dose 400mg
KH173 + KH183: Percentage of Administered Dose Excreted in Urine: MAD20.7 ± 79.317.4 ± 33.319.0 ± 17.9

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group I Placebo0/6 (0%)0/6 (0%)2/6 (33.3%)
Group II Placebo0/6 (0%)0/6 (0%)1/6 (16.7%)
SAD Group I 10mg0/4 (0%)0/4 (0%)2/4 (50%)
SAD Group II 30mg0/4 (0%)0/4 (0%)3/4 (75%)
SAD Group I 100mg0/4 (0%)0/4 (0%)4/4 (100%)
SAD Group II 300mg0/4 (0%)0/4 (0%)1/4 (25%)
SAD Group I 800mg0/4 (0%)0/4 (0%)0/4 (0%)
SAD Group II 2000mg0/4 (0%)0/4 (0%)4/4 (100%)
Group I Placebo + Food0/2 (0%)0/2 (0%)1/2 (50%)
Group I 100mg + Food0/4 (0%)0/4 (0%)1/4 (25%)
MAD Group III 200mg0/4 (0%)0/4 (0%)3/4 (75%)
MAD Group IV 400mg0/4 (0%)0/4 (0%)3/4 (75%)
MAD Group V 800mg0/4 (0%)0/4 (0%)4/4 (100%)
Placebo0/6 (0%)0/6 (0%)5/6 (83.3%)
Most frequent other events
Showing 10 of 44
Most frequent other events
EventGroup I PlaceboGroup II PlaceboSAD Group I 10mgSAD Group II 30mgSAD Group I 100mgSAD Group II 300mgSAD Group I 800mgSAD Group II 2000mgGroup I Placebo + FoodGroup I 100mg + FoodMAD Group III 200mgMAD Group IV 400mgMAD Group V 800mgPlacebo
DizzinessNervous system disorders2/60/60/42/43/41/40/43/40/20/40/40/40/41/6
HeadacheNervous system disorders2/60/60/41/43/40/40/41/40/20/42/41/41/43/6
Paraesthesia oralGastrointestinal disorders0/60/60/40/40/40/40/43/40/20/40/40/40/40/6
Electrocardiogram QT prolongedInvestigations0/60/60/40/40/40/40/43/40/20/40/40/41/40/6
Brundle branch block rightCardiac disorders0/60/60/40/40/40/40/42/40/20/40/40/40/40/6
NauseaGastrointestinal disorders1/60/60/40/40/40/40/42/40/20/40/40/41/42/6
VomitingGastrointestinal disorders0/60/60/40/40/40/40/42/40/20/40/40/40/40/6
Eosinophil count increasedInvestigations0/60/60/40/40/40/40/40/41/20/40/40/40/40/6
Skin irritationSkin and subcutaneous tissue disorders0/60/60/40/40/40/40/40/40/20/40/41/42/42/6
Lipase increasedInvestigations0/60/60/40/40/40/40/40/40/20/40/40/42/40/6

Baseline characteristics

SAD:14 subjects divided in two groups of 7 subjects were included. Two subjects prematurely withdrew from the study after dosing period 2 for non-medical reasons. MAD part:18 subjects divided in 3 groups of 6 subjects were included. Two subjects prematurely withdrew from the study for non-medical reasons and were replaced.

Age, Continuous
Age, Continuous(years)SAD Group ISAD Group IIMAD Group IIIMAD Group IVMAD Group VPlaceboTotal
Mean30.4 ± 10.532.0 ± 11.340.8 ± 13.034.5 ± 11.644.0 ± 8.244.7 ± 9.840.0 ± 4.0
Sex: Female, Male
Sex: Female, Male(Participants)SAD Group ISAD Group IIMAD Group IIIMAD Group IVMAD Group VPlaceboTotal
Female0000000
Male77444632
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SAD Group ISAD Group IIMAD Group IIIMAD Group IVMAD Group VPlaceboTotal
Hispanic or Latino1001013
Not Hispanic or Latino67434529
Unknown or Not Reported0000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SAD Group ISAD Group IIMAD Group IIIMAD Group IVMAD Group VPlaceboTotal
American Indian or Alaska Native0000000
Asian0000000
Native Hawaiian or Other Pacific Islander0000000
Black or African American0000000
White77444632
More than one race0000000
Unknown or Not Reported0000000
Region of Enrollment
Region of Enrollment(participants)SAD Group ISAD Group IIMAD Group IIIMAD Group IVMAD Group VPlaceboTotal
Belgium77444632
Height
Height(cm)SAD Group ISAD Group IIMAD Group IIIMAD Group IVMAD Group VPlaceboTotal
Mean178.07 ± 6.56176.01 ± 8.11184.63 ± 2.81181.75 ± 5.25175.70 ± 3.18175.55 ± 8.25184.0 ± 4.0
Weight
Weight(kg)SAD Group ISAD Group IIMAD Group IIIMAD Group IVMAD Group VPlaceboTotal
Mean82.86 ± 10.5674.29 ± 12.6189.05 ± 11.8477.85 ± 11.9681.10 ± 4.8272.03 ± 6.0680.0 ± 8.0
BMI
BMI(kg/m^2)SAD Group ISAD Group IIMAD Group IIIMAD Group IVMAD Group VPlaceboTotal
Mean26.09 ± 2.5124.01 ± 4.0126.10 ± 2.7423.60 ± 3.8226.28 ± 1.6723.43 ± 1.9824.0 ± 4.0
08

Study locations

1 site
  • Drug Research Unit Ghent
    Ghent, Belgium
09

References and documents

Publications

  • Koene S, Spaans E, Van Bortel L, Van Lancker G, Delafontaine B, Badilini F, Beyrath J, Smeitink J. KH176 under development for rare mitochondrial disease: a first in man randomized controlled clinical trial in healthy male volunteers. Orphanet J Rare Dis. 2017 Oct 16;12(1):163. doi: 10.1186/s13023-017-0715-0. PubMed 29037240 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2015, a primary completion of Sep 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2020, 5 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2015
First posted
Sep 9, 2015
Start
May 2015
Primary completionActual
Sep 2015
CompletionActual
Oct 2015
Results first posted
Nov 12, 2020
Last update
Oct 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02544217
Lead sponsor
Khondrion BV
Collaborators
University Ghent
Responsible party
Sponsor
First posted
Sep 9, 2015
Start date
May 2015
Primary completion
Sep 2015
Completion
Oct 2015
Results posted
Nov 12, 2020
Last update
Oct 18, 2021

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trolox

Start the discussion